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Abstract 
Keratolytic winter erythema (KWE) is a rare autosomal dominant skin disorder characterized 
by recurrent episodes of palmoplantar erythema and epidermal peeling, and symptoms 
worsen in winter. KWE is relatively common in South African (SA) Afrikaners and was 
mapped to 8p23.1-p22 through a common haplotype in SA families. The aim of this study 
was to identify and characterize the causal mutation for KWE in SA families. 
 
 
Targeted resequencing of 8p23.1-22 was performed in three families and seven unrelated 
controls. Reads were aligned to the reference genome using BWA. GATK and Pindel were 
used to call small and large structural variants, respectively. A 7.67 kb tandem duplication 
was identified upstream of the CTSB gene and encompassing an enhancer element that is 
active in a keratinocytes (based on H3K27ac data). The tandem duplication segregated 
completely with the KWE. The tandem duplication overlaps with a 15.93 kb tandem 
duplication identified in two Norwegian families at a 2.62 kb region encompassing the active 
enhancer suggesting that the duplication of the enhancer leads to the KWE phenotype.  
 
 
Existing chromatin structure, CTCF binding and chromatin interaction data from several cell 
lines, including keratinocytes were analysed and three potential topological subdomains 
were identified, all containing the enhancer and CTSB, or CTSB and FDFT1 or both genes and 
NEIL2. Additionally, we showed that the enhancer’s activity correlated with CTSB expression, 
but not with FDFT1 and NEIL2 expression in differentiating keratinocytes and other cell lines. 
RNA polymerase II ChIA-PET interaction data in cancer cell lines showed that the enhancer 
interacts with CTSB but not FDFT1 or NEIL2. These data suggest that the enhancer normally 
regulates CTSB expression. Relative gene expression and immunohistochemistry from 
palmar biopsies from South African and Norwegian participants (7 Affected and 7 Controls) 
showed a significantly higher expression of CTSB, but not FDFT1 and NEIL2, in affected 
individuals compared to the controls and that CTSB was significantly more abundant in the 
granular layer of affected individuals compared to controls. We conclude that the enhancer 
duplication causes KWE by upregulating CTSB expression and causing an overabundance of 
CTSB in the granular layer of the epidermis.  
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Chapter 1 
 
Introduction and Literature Review 
 
Keratolytic Winter Erythema (KWE; MIM 148370) is a rare autosomal dominant skin disorder 
of unknown aetiology.  It is characterized by cyclical redness (erythema), epidermal layer 
thickening and the formation of dry blisters where centrifugal skin peeling originates at the 
palms and soles (Findlay and Morrison, 1978; Findlay et al., 1977; Hull, 1986). Interestingly, 
the symptoms appear to worsen in winter in many of the affected individuals. KWE globally 
rare, but fairly common in South African Afrikaners and Coloureds, as a result of genetic drift 
by founder effect in South African families (Hull, 1986; Starfield et al., 1997). In 1997, the 
KWE mutation was localised to chromosome 8p23.1-p22, between and including markers 
D8S550 and D8S1759, a region referred to as the KWE critical region (Appel et al., 2002; 
Starfield et al., 1997). Previous research approaches, such as candidate gene sequencing and 
gene expression analysis (Appel et al., 2002; Hobbs et al., 2012; Hull et al., 2013), proved 
insufficient in identifying the KWE causal mutation which remained elusive for twenty years 
following its localization to chromosome 8p. In this study, a new approach using targeted 
capture resequencing of the KWE critical region led to the identification of the causal 
mutation for KWE.  
 
 
1.1. The skin 
The skin, also known as the integument, is the largest organ making up approximately a sixth 
of the body weight (Hirobe, 2014; Wickett and Visscher, 2006). Hair, nails, skin oil, sweat 
gland are regarded as skin derivatives. The skin prevents water loss, synthesises vitamin D, 
and serves as the body’s shield against environmental factors such as temperature 
fluctuations, radiation, infection, toxins and injury (Groenendaal et al., 2010; Nestle et al., 
2009; Nithya et al., 2015; Wickett and Visscher, 2006). The skin is a flexible, continuously 
regenerating organ with varying thickness and varying metabolic state with age and 
environmental cues such as injury. The skin also harbours a complex microbiome (Grice et 
al., 2008) which helps to maintain skin health and varies between individuals depending on 
diet, environmental exposure and genetics. The microbiome may be protective against 
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pathogens or make individuals more susceptible to infection based on the composition and 
balance in bacteria and microflora on the skin. The skin is susceptible to a variety of diseases 
as a result of environmental exposures such as ultraviolet (UV) radiation which may lead to 
certain forms of cancer, exposure to pathogens which may lead to infection, allergens and 
harmful chemicals. Additionally skin may become dysregulated or abnormal due to genetic 
causes.  
 
 
1.1.1. The layers of the skin 
The skin is made up of three layers, namely the layer of subcutaneous fat, the dermis and 
the epidermis (Figure 1.1) (Hirobe, 2014), and disruption in the regulation of the formation 
and maintenance these layers may lead to disease. 
 
 
Figure 1.1:  A schematic representation of the three layers that make up human skin 
(From http://www.healthoncare.com/basic-human-skin-structure-functions-skin-care/) 
 
The subcutaneous fat layer is the innermost layer of the skin that varies in thickness based 
on the location of the skin on the body. This layer attaches the rest of the skin to the muscle 
layers beneath through its connection to the dermis and covers the skeleton, muscles and 
other organs to maintain the structural integrity of the body. It also creates a physical barrier 
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between the environment and internal organs, bones and muscles by storing fat which acts 
as a cushion protecting bones and muscles from external physical pressure while also acting 
as an energy source for the organ (Osman et al., 2013). This layer also controls body 
temperature by acting as a heat and cold insulator. It made up of adipose tissue, and is the 
initial entry point of blood supply and nerves from the body to the skin. 
 
 
The dermis is the multifunctional middle layer of the skin and is responsible for the skin’s 
elasticity and strength which are achieved through the presence of different collagens and a 
wide range of proteins (Groenendaal et al., 2010; Osman et al., 2013). It also plays a major 
role in temperature regulation. The dermis has two collagen rich layers; the papillary and 
reticular layer (Osman et al., 2013). The papillary layer attaches the dermis to the epidermis 
whereas the reticular layer holds the major components of the dermis including the sweat 
glands and is responsible for the dermis’s strength and elasticity (Osman et al., 2013). The 
dermis comprises mainly of fibroblasts, adipocytes and macrophages. It receives oxygen and 
nutrients through the vasculature which also serves to remove waste products. The blood 
vessels also serve in regulating body temperature in response to heat and cold by dilating or 
contracting to increase or decrease blood circulation to the surface of the skin thereby 
releasing or conserving heat.  
 
 
The skin also regulates body temperature through skin appendages such as the sweat 
glands, hair follicles, sebaceous glands and sweat glands (Xie et al., 2016). Sweat glands 
produce sweat in response to stress and heat. Hair follicles stem from the epidermis and also 
regulate temperature, enhance skins sensation and act as physical barrier from injury. The 
number of hair follicles varies across the body and are absent on palmoplantar skin. The 
dermis also has nerve endings that sense environmental stimuli such as heat, cold, pain and 
pressure. Sebaceous glands produces oils that regulate the skins softness and moisture while 
acting as a barrier against alien substances and pathogens and rendering the skin 
waterproof. 
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1.1.2. The epidermis 
The dermis and epidermis are separated by a basement membrane made of a complex of 
glycoproteins and proteoglycans (Breitkreutz et al., 2013). This membrane extends to the 
outer regions of the skin derivatives such as hair. The epidermis is the outmost, multi-
layered layer of the skin made of stratified squamous epithelia and serves as the first line of 
defence against UV radiation, physical, thermal, pathogen and toxic insults from the 
environment (Hirobe, 2014). Unlike the dermis, the epidermis is avascular. The epidermis 
mainly comprises keratinocytes but also has Langerhans cells and lymphocytes (immune 
cells), Merkel cells (touch sensitivity) and melanocytes (produces melanin) (Nakatani et al., 
2015; Wickett and Visscher, 2006).  Keratinocytes and keratinocyte differentiation will be 
discussed in section 1.1.2.1. 
 
 
Langerhans cells are antigen presenting dendritic immune cells located in the basal layer of 
the epidermis and in epithelia of digestive, respiratory and urogenital tracts. They protect 
the epidermis from infection but also allow tolerance of commensal bacteria by the skin. 
These cells perform their function by acquiring antigens and presenting the antigens to naïve 
T-Cells in the lymph nodes for the initiation of an adaptive immune response (Chomiczewska 
et al., 2009). 
 
 
Epidermal Merkel cells are non-neural cells found in the dermal/epidermal border of highly 
tactile regions (eg. fingertips) of the skin (Morrison et al., 2009; Nakatani et al., 2015). The 
exact function of Merkel cells is unknown but they are thought to be  important in the 
detection of shape, texture and curvature along with the ability to discriminate between two 
distinct points touching the skin at the same time (Morrison et al., 2009). 
 
 
Melanocytes are found in the basal layer of the skin (section 1.1.2.1) and are responsible for 
skin pigmentation through their production of melanin. These cells contain melanosomes 
which contain melanin which are transferred from the melanocytes to the keratinocytes 
resulting in energy absorption from the sun to protect against UV radiation and provide 
colour to the skin. The process of melanin production and melanosome transfer happens 
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concurrently with epidermal renewal but may be accelerated by excess sun exposure 
(Wickett and Visscher, 2006). 
 
 
1.1.2.1. Structure of the epidermis and epidermal differentiation 
The epidermis accounts for 3.7–16.8%  and 40.6–44.6% of the dorsal and palmoplantar skin 
respectively (Lee and Hwang, 2002) and the epidermis is primarily composed of 
keratinocytes (Wickett and Visscher, 2006). Depending on gender, age and the skin’s 
location on the body, the thickness of the epidermis varies between 30-105 µm for skin 
across the body and 601–637 µm on palmoplantar skin (Lee and Hwang, 2002; Saager et al., 
2015; Sandby-Moller et al., 2003; Whitton and Everall, 1973). The epidermis is not flat but 
rather has rete ridges that interlock the epidermis to the dermis.   
 
 
Keratins 
Keratinocytes primarily produce keratin which is a major structural protein of the epidermis 
and aids in the barrier function of the epidermis by forming the structural framework of 
keratinocytes and other epithelial cells (Hirobe, 2014). There are 54 known functional 
keratin genes that are divided into two groups (Moll et al., 2008, Schweizer et al., 2006). The 
first group, type I, has 28 keratins (17 epithelial and 11 hair keratins) which are small, acidic 
(pH 4.5-4.5) keratins, whose genes are located on chromosome 17q21.2 (except keratin 18 
(KRT18); located at 12q13.13) (Schweizer et al., 2006, Moll et al., 2008). The second group, 
type II, has 26 keratins (20 epithelial and 6 hair keratins) which are large, basic to neutral (pH 
5.5-7.5) keratins whose genes are located on chromosome 12q13.13 (Moll et al., 2008, 
Schweizer et al., 2006). Keratin sizes range from 44-66 kDa (Moll et al., 2008). Epithelial 
keratins are listed in Table 1.1. Additionally, keratins form heterodimers composed of a 
combination of keratins from type I and II (1 type I/1 type II), to make keratin intermediate 
filaments (KIF), some specific to each epidermal layer (Moll et al., 2008). KIFs form 
tonofilaments that attach desmosomes (composed of desmosomal cadherins) or 
hemidesmosomes (composed of α6β4-integrin-containing) which are intercellular 
connections that connect keratinocytes to each other and to the basal membrane 
(hemidesmosomes) (Blanpain and Fuchs, 2006; Smith et al., 2004). The disturbance of the 
keratinisation process by altered expression keratins and the other genes involved in 
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keratinisation results in a variety of skin disorders. Alteration of keratinisation at any of the 
layers of the epidermis can cause a range of disorders including keratolytic winter erythema 
(KWE) which will be discussed in section 1.2. 
 
Table 1.1: Human Type I and Type II epithelial keratins 
Category Number range Location pH 
Human type I epithelial keratins 9-28 17q21.2 Acidic 
Human type II epithelial keratins 1-8 and 71-80 12q13.13 Basic-neutral 
Human type I epithelial keratins KRT18 2q13.13 Acidic 
 
 
Other regulators of epidermal differentiation 
Environmental and intrinsic factors such as the innate immune system, a calcium gradient, 
steroid metabolism, growth factors and drug reactions affect differentiation (Banno and 
Blumenberg, 2014; Gilbert, 2000). Although keratins play a major role in differentiation and 
the formation of corneocytes, other groups of genes are also essential in differentiation and 
a few examples are given below.  
 
 
The epidermal differentiation complex on chromosome 1q21 comprises: (1) cornified 
envelope precursors loricrin, involucrin, small proline-rich proteins (SPRR) and the late 
cornified envelope proteins (LCE); (2) calcium-binding proteins (S100) and (3) the S100 fused 
proteins (filaggrin, filaggrin-2, trichohyalin, trichohyalin-like protein, hornerin, repetin and 
cornulin) (Volz et al., 1993, Kypriotou et al, 2012). Desmosomes are essential intercellular 
junctions that allow keratinocytes to adhere to each other and the genes involved in 
maintaining desmosomes are also important in the regulation of keratinocyte 
differentiation. The cadherin, armadillo and plakin protein families are major constituents of 
desmosomes and mutations in the genes coding for these proteins have been shown to alter 
differentiation. The desmocollin and the desmoglein subfamilies form the cadherin family 
and are coded for by the desmocollins (DSC) and desmogleins (DSG) (Smith et al., 2004). 
Mutations in DSG1 have been shown to cause autosomal dominant striate palmoplantar 
keratoderma (Rickman et al., 1999).  
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Transglutaminases are essential for cross linking proteins to make the cornified envelope 
(CE), and therefore its proper regulation is important in keratinisation (Nithya et al., 2015). 
Cathepsins which are found in lysomes and lamellar granules (cathepsin V) along with 
transglutaminases also play an important role in differentiation and the development of the 
cornefied envelope as they regulate transglutaminases (Eckhart et al., 2013). Some 
cathepsins activate key transglutaminases such as transglutaminases 3 (activated by 
cathepsin L) (Eckhart et al., 2013). Cathepsin D regulates the transglutaminase 1 which is 
important in forming the CE (Egberts et al., 2004). Calcium influx is also important in 
transglutamination as it activates the pathway (Eckhart et al., 2013). 
 
 
Keratinisation of the epidermis 
The epidermis has four distinct layers (five in palmoplantar skin) (Figure 1.2) with distinct 
keratinocyte morphology, gene expression, keratin and lipid composition (Nestle et al., 
2009). The layers of the epidermis are the stratum basale, stratum spinosum, stratum 
granulosum and the stratum corneum (preceded by the stratum lucidum in palmoplantar 
skin) and these cells are connected to each other through desmosomes (calcium dependant 
cell adhesion glycoproteins) (King et al., 1991). The basal layer and the spinosum layers make 
up the Malpighian layer (Gilbert, 2000). The basal layer is connected to the basement 
membrane through the hemidesmosomes. The basement membrane allows nutrient 
diffusion from the dermis to the basal layer. The epidermis is constantly regenerating 
through a process of self-renewing and desquamation (shedding) and it does this through a 
balanced process of cell proliferation and cell death during a process known as keratinisation 
(Alonso and Fuchs, 2003). Keratinocytes are produced by the basal layer and differentiate 
through keratinisation to form the stratum corneum which comprises terminally 
differentiated dead keratinocytes also known as corneocytes that lack nuclei and 
cytoplasmic organelles (Bouwstra and Ponec, 2006). These corneocytes (dead keratinocytes) 
are the building blocks of the epidermis barrier (Eckhart et al., 2013). 
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Figure 1.2: A schematic representation of the layers that make up epidermis in 
palmoplantar skin 
The figure shows keratinocytes at different stages of differentiation and non-keratinocyte 
cells (Langerhans, Merkel and melanocytes) that overlap with the epidermis. Cells within the 
epidermis are joined together by desmosomes indicated as black lines connecting the cells. 
(From: http://www.pamperbay.co.uk/?p=54). 
 
 
Stratum Basale 
The stratum basale (basal  or germinativum cell layer)  is the innermost layer of the 
epidermis and contains multipotent keratinocyte stem cells and transient amplifying  
keratinocytes that give rise to the rest of the epidermis (Alonso and Fuchs, 2003; Banno and 
Blumenberg, 2014).  The stem cells produce transforming growth factor-α (TGF-α) which 
        Basement membrane 
Suprabasal  
layer 
Malpighian  
layer 
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induces more cell division, producing basal  daughter  cells (Gilbert, 2000). The daughter cells 
either become stem cells or transiently amplifying keratinocytes which  will commit to 
terminal differentiation (Alonso and Fuchs, 2003). Transient amplifying cells proliferate and 
after 3-6 rounds of mitosis, they withdraw from cell division to commit to cell differentiation 
by detaching from the basement membrane, initiating cell differentiation (Alonso and Fuchs, 
2003). Additionally, integrin and laminin expression (forms part of the basement membrane) 
is inactivated and negative regulators of proliferation, lipid and steroid enzymes, are induced 
thereby initiating cell differentiation (Blanpain and Fuchs, 2006). The major keratins 
expressed in the basal epidermis layer are the K5 and K14 keratins, and K15 is the minor 
keratin (Blanpain and Fuchs, 2006). These keratins form a K5/K14 complex along with 
microtubules (tubulin) and microfilaments (actin), to form the keratinocytes cytoskeleton. 
The K5/K14 KIFs form tonofilaments that connect to α6β4-integrin-rich hemidesmosomes to 
anchor the basal layer to the laminin5-rich extracellular matrix of the basement membrane 
(Blanpain and Fuchs, 2006; Moll et al., 2008). K15 has also been shown to be expressed in 
the basal layer cells of young children (up to 1.5 years), and expression is decreased in 
adults, and it is localised to the rete ridges in adult skin (Moll et al., 2008; Pontiggia et al., 
2008). As the basal keratinocytes move upward, the expression of K5,  K14 and the integrin’s 
reduce and these keratins are no longer expressed when the cells progress to the spinous 
layer cells (Fuchs and Green, 1980; Gilbert, 2000). These cells then migrate upward to 
become the new spinous layer  of keratinocytes (Banno and Blumenberg, 2014).  
 
 
Stratum spinosum 
The cells in the 4-8 layer spinous layer appear prickly and form desmosomes that connect 
cells to each other (Fuch, 1990). These cells are no longer dividing but are metabolically 
active (Fuch, 1990). The cytoskeleton of the cells in this layer is formed by a complex 
containing K1/K10 KIFs which are in close proximity to the euchromatic nucleus and 
attached to the desmosomes. In palmoplantar skin, K2 forms a complex with K10 (K2/K10, 
expressed in upper stratum spinosum, stratum granulosum) (Moll et al., 2008; Wallace et al., 
2012). Keratin 9 (K9) is also expressed in this layer with K9 forming dimers with K1 in 
palmoplantar skin (Moll et al., 2008; Wallace et al., 2012). The keratinocytes are anchored 
together by desmosomes and the cytoplasm also contains melanosomes. Additionally, these 
cells produce membrane coating proteins and involucrin (glutamine and lysine-rich envelope 
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protein incorporated into the inner surfaces plasma membranes) (Rice and Green, 1979 as 
cited by Fuchs, 1990). The involucrin is transported to the desmosmes where it binds to the 
plakins and initiates the formation of the CE (Kypriotou et al., 2012).       
 
                                                                                                                                                                                   
Stratum granulosum  
As the cells in the basal layer proliferate, the cells in the spinous layer move upward to form 
the stratum granulosum (granular layer). These cells have a flattened appearance and 
undergo extensive cellular changes in preparation for forming the horny layer. The cells 
contain granules of keratin (Gilbert, 2000). The chromatin in the nuclei condenses then the 
nucleus disintegrates. The mitochondria, Golgi apparatus and ribosomes also disintegrate. 
Loricrin, a major structural protein of the CE is also synthesised in this superficial layer of the 
granular layer (Rice and Green, 1979 as cited by Fuchs, 1990). The cytoplasm is then 
occupied by lamellar granules (concentrated in the plasma membrane) and keratin filaments 
which become compact and associate with keratohyalin granules. The keratohyalin granules 
contain profilaggrin which is modified to filaggrin in the stratum corneum and loricrin cross-
linked to involucrin (Nithya et al., 2015; Wickett and Visscher, 2006). The lamellar granules 
have an essential function in forming the epidermis permeability layer, allowing it to be 
waterproof. The lamellar granules primarily compact in the plasma with which they fuse to 
release hydrophobic glycophospholipid contents into the intercellular spaces within the 
granular layer and between the stratum granulosum and the stratum corneum. The 
formation of the cornified envelope starts in the granular layer due to the production of 
many of the CE’s components in this layer (Nithya et al., 2015). 
 
 
Stratum lucidum 
The stratum lucidum, presents only in palmoplantar skin is an additional layer of clear, flat, 
dead keratinocytes filled with eleidin (a keratin intermediate).  In palmoplantar skin, 
granular layer cells migrate to form the stratum lucidum which migrate to form the stratum 
corneum. 
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Stratum corneum  
Granulated keratinocytes migrate upward to form the final product of terminal 
differentiation, the stratum corneum (horny layer). The stratum corneum is the outermost 
layer and functions as the barrier whereas the rest of the epidermis functions in generating 
and maintaining the stratum corneum (Bouwstra and Ponec, 2006). The keratinocytes in this 
layer, often referred to as corneocytes are large, flat cells filled with keratin (Nithya et al., 
2015). They lack nuclei and organelles consist of keratin filaments embedded in a filaggrin 
(once cells reach the horny layer, profilaggrin is modified to make filaggrin) rich cytoplasmic 
matrix. Corneocyte plasma membranes appear much thicker due to the cross-linking by 
transglutaminination  of several proteins from the epidermal differentiating complex (EDC) 
including involucrin (soluble), loricrin and small proline rich proteins (SPRPs) with the 
insoluble plasma membrane, the lipid and lamellae crosslinked to form the cornified 
envelope (Eckhart et al., 2013; Nithya et al., 2015; Wikramanayake et al., 2014). 
Transglutaminination is catalysed by transglutaminases 1,3 and 5 which are  activated by a 
calcium influx (Eckhart et al., 2013; Nithya et al., 2015; Wikramanayake et al., 2014). Other 
major proteins in the CE include desmosomal proteins, KIFs, cystatin A and elafin (Nemes 
and Steinert, 1999; Nithya et al., 2015). Corneocytes outer membranes also have a layer of 
lipid which accounts for 15% of the cell content and comprised mainly of ceramides, 
cholesterol, and free fatty acids which all help build the physical barrier (Wilkes et al., 1973). 
The number of layers in the horny layer range from a few layers in trunk skin to 50 layers in 
palmar or plantar skin. The horny layer is constantly being pushed up by cells from the lower 
epidermal layer leading to the shedding of uppermost horny layer cells in a process known 
as desquamation. 
 
 
The correct maintenance of the keratinocyte differentiation is crucial in the formation and 
maintenance of the stratum corneum. When this tight regulation is altered, keratinocyte 
related skin disorders may arise and these can affect the trunk skin and/or the palmoplantar 
skin. In this study, we discuss keratolytic winter erythema, a disorder where the formation pf 
the stratum corneum is altered leading to the disease phenotype. 
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1.2. Keratolytic Winter Erythema 
Keratolytic Winter Erythema (KWE, OMIM: 148370) or Erythrokeratolysis hiemalis is a rare 
skin disorder of unknown aetiology. The disorder was first named and clinically defined by 
Findlay and colleagues (Findlay et al., 1977) and described in families residing in Oudtshoorn 
(Western Cape, South Africa, Figure 1.3), or whose roots could be traced to back to 
Oudsthoorn. KWE is therefore also known as “Oudtshoorn Skin” (Findlay and Morrison, 
1978; Findlay et al., 1977; Hull, 1986). Although most of the patients were from Oudtshoorn, 
many now live across the country or have moved to other countries such as Zimbabwe, the 
United Kingdom and Canada (Hull, 2016, personal communication). KWE has also been 
described in Germany (Starfield et al., 1997) Denmark (Danielsen et al., 2001) the USA (in a 
family of Norwegian descent) (Huntington and Jassim, 2006) and in the UK (in a family linked 
to the South African pedigrees)(Amin et al., 2011). 
 
 
 
 
 
 
 
Figure 1.3: Oudtshoorn shown on the map of Western Cape within the South Africa map 
Oudtshoorn is shown as the yellow city on the Western Cape map (From 
http://www.drodd.com/html7/south-african-map.html) 
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1.2.1. Clinical characterization of KWE 
KWE is characterized by intermittent and recurrent centrifugal peeling, with initial 
palmoplantar redness (erythema), keratin layer thickening and formation of superficial dry 
blisters where centrifugal skin peeling originates (Figure 1.4). The affected skin dissects off to 
form a peel which proceeds centrifugally to the major skin creases where a mild 
hyperkeratosis develops (Hull, 1986, Hull et al., 2013). Centrifugal peeling appears at 
multiple palmoplantar sites and is arrested at the major skin creases. The lesions start as red 
multi-forme like papules which enlarge and have red, sometimes thickened edges. Dry bulla 
which may be exudative and eventually dissect off from the centre outwards removing the 
stratum corneum as a though elastic scale that is adherent and not disturbed by friction but 
can be peeled off when moistened (Findlay and Morrison, 1978; Findlay et al., 1977). Once 
the stratum corneum peels off the palms and soles appear red and wrinkled. 
 
 
a.  
 
b.                                                                                  c.  
Figure 1.4: KWE patients showing the erythema and peeling of palmar and plantar surfaces 
and the web space 
The peeling occurs on the palms (A), soles (B) and web spaces (C). (Photograph Credit: by 
Peter Hull). 
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The erythema and peeling may spread to the fingers/toes and web spaces, and occasionally 
dorsal regions may be affected. In all cases, the palms and soles are affected but in some 
cases, annular scaling erythema on the knees, forearms, hips, buttocks, legs and thighs, 
shoulders, spine and the dorsal have been reported (Findlay and Morrison, 1978; Findlay et 
al., 1977). A palmoplantar cold sweat with a distinct odour, accompanies aggravated peeling 
and occurs mainly in winter but may also be observed in the summer, or as a result of other 
triggers, for example excessive exposure to water or during infections (Findlay et al., 1977; 
Hull, 1986). Hyperkeratosis lasts for 6-8 weeks and itching at the affected regions has been 
reported in some cases (Findlay and Morrison, 1978; Findlay et al., 1977). 
 
 
1.2.2. Nosology of KWE 
There is no clear published systematic classification (nosology) of KWE, but expert 
dermatologists familiar with KWE have classed KWE as an erythrokeratoderma (Hull, 2016, 
personal communication). Erythrokeratodermas are a clinically and genetically 
heterogeneous group of disorders. This group of disorders has several overlapping features 
with KWE in that they rare inherited skin disorders, manifest at an early age and are 
characterised by well demarcated erythema and hyperkeratotic plaques and many show 
variable expressivity and incomplete penetrance (Hohl, 2000; Ishida-Yamamoto et al., 1997). 
As is the case for KWE, the cell nuclei are usually not fully disintegrated by the time the 
keratinocytes reach the final layer (see section 1.2.3) (Hohl, 2000; Ishida-Yamamoto et al., 
1997). Symptoms may be influenced by environmental factors such as temperature, stress 
and mechanical pressure (Karadag et al., 2013; Mahajan et al., 2015). Initially, there were 
two main subtypes of erythrokeratodermas namely progressive symmetric 
erythrokeratoderma (PSEK) and erythrokeratoderma variabilis (EKV) (Hohl, 2000, Rogers, 
2005) but these two disorders have now been consolidated as one disorder, 
erythrokeratodermia variabilis et progressiva (EKVP). This was mainly due to the fact that 
both disorders were identified in the same family and the people who had the different 
disorders shared common mutations (Richard et al., 2003; van Steensel et al., 2009). The 
plaques can either be migratory or stationary which led to initial characterisation of EKVP as 
two separate disorders, EKV and PSEK (Hohl, 2000; Ishida-Yamamoto et al., 1997). Most 
EKVPs are inherited in an autosomal dominant manner, but autosomal recessive cases 
(Gottfried et al., 2002) have also been reported. EKVP affects the trunk skin and 
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palmoplantar skin in some instances (Ishida-Yamamoto et al., 1997; Richard et al., 2000). 
EKVP has been shown to be caused by mutations in the gap junction protein alpha and beta  
genes (GJA1, GJB2 and GJB4) (Gottfried et al., 2002; Richard et al., 2003; Richard et al., 2000; 
van Steensel et al., 2009; Wilgoss et al., 1999) and the loricrin gene (Ishida-Yamamoto et al., 
1997). 
 
 
1.2.3.  Histological and microscopic findings  
Haemotoxylin and Eosin (H&E) staining of affected skin clearly shows that the epidermis of 
affected skin is not normal as peeling and an abnormal parakeratotic layer were noted in the 
skin of affected individuals (Figure 1.5) (Hull et al., 2013). By evaluating 40 biopsies from 18 
patients, Findlay and Morrsion (1978) conducted the first light microscopy evaluations to 
determine the pathogenesis of KWE at a cellular level. Two major processes were observed: 
(1) at the rear end of the lesion, necrobiosis of the Malphighian layer with the absence of a 
stratum granulosum occurs; and (2) the presence of spongiosis and vesicles outside the 
lesion.   
 
 
Figure 1.5: Haemotoxylin and Eosin (H&E) stained palm biopsy of a KWE patient.  
The layer of parakeratosis (indicated by the arrows) is sandwiched between the old 
orthokeratotic stratum corneum and the re-established orthokeratotic layer (Hull et al., 
2013). 
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1.2.3.1. Light microscopy 
In this section, the light microscopy findings by Findlay and Morrison (1978) will be 
summarized. The Malphighian layer does not appear normal as it appeared that the 
Malphighian thickness and rete ridge prolongation was significantly reduced when viewed 
under the microscope. The peeling of the skin is caused by cell death (necrobiosis) of some 
keratinocytes, the failure of keratinocytes in the Malphighian layer to undergo normal 
keratinization and the absence of an overlaying normal granular layer.  
 
 
The granular layer thickens with the destruction of the Malphighian layer and the granular 
cells may undergo necrobiosis forming “granular cell ghosts”. These granular cell ghosts have 
a regular granular shape and size, but each lacks a nucleus and granules and forms a granular 
monolayer of granular ghost cells that occupy the stratum lucidum space. Necrobiosis is 
evidenced by visible nuclear changes including nuclear shrinkage and fragmentation which 
are associated with cell death. 
 
 
The lesion spreads horizontally across the Malphighian layer and spongiosis and vesicles 
covered by a granular layer may also be observed just outside the lesion. A 2-8 cell layer 
parakeratotic lamina forms and this triggers epidermal recovery which results in the 
parakeratotic lamina being pushed out of the epidermis by the recovering layers below it. 
The recovery is achieved by basal cell proliferation, although maturation of these basal cells 
is halted due to the defects in the Malphighian layer. The basal cells often show spongiosis 
and necrobiosis and form block-like masses which engulf melanocytes. The parakeratotic 
layer then appears sandwiched between the original normal orthokeratotic stratum 
corneum and the new orthokeratotic stratum corneum below the parakeratotic layer. The 
split occurs above the newly formed stratum corneum and forms a substantial peel as shown 
in Figure 1.5 (Hull et al., 2013). As the lesion proceeds centrifugally, the centre of the lesion 
is restored. 
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1.2.3.2.    Electron Microscopy 
In this section, the electron microscopy findings by from Peter Hull’s PhD thesis (1986) will 
be summarized. By evaluating biopsies from five patients, Hull noted a normal dermis and 
basement membrane. Hull concluded that there were no structural abnormalities, only the 
secondary changes discussed in this section including spongiosis, keratinocyte mitochondrial 
changes and the presence of perinuclear vacuoles. 
 
 
Focal spongiosis (fluid accumulation) between the keratinocytes of affected individuals 
resulting in expanded intercellular spaces were observed. Cells outside these spongiotic 
areas appeared normal and seemed to be undergoing normal keratinisation.  The spongiosis 
was most pronounced in the intact basal layer which remained intact with normal 
hemidesmosomes, and extended to the rest of the Malphighian layer and was less 
pronounced in the granular layer (Hull, 1986). The number of desmosomes was significantly 
decreased in the spongiotic spaces and desmosomes within the epidermis, connecting 
keratinocytes to each other, appeared stretched although they had normal morphology. 
Within the intercellular spongiotic space, desmosomes were often freely floating without 
any cellular attachment. The spongiotic areas also included membrane bound cytoplasmic 
material containing organelles but lacking the structural supportive tonofibrils. Langerhans 
cells within their dendrites along with Merkel cells were seen floating freely in the expanded 
intercellular spaces.  
 
 
The keratinocytes also showed marked changes particularly in the mitochondria which 
showed intra-cristae swelling which is a result of a water influx into the outer chamber of the 
mitochondrial cristae. The movement of water from the mitochondrial matrix into the inter-
membranous spaces resulted in a denser matrix and occasional inter-membranous 
blistering. Eventually progressive granular mitochondrial degeneration occurs, resulting in 
perinuclear lucid vacuoles. These vacuoles occupy a large section of the cytoplasm and they 
distort and displace the nuclei of the granular layer keratinocytes. These mitochondrial 
changes were only seen in keratinocytes as the mitochondria of the lymphocytes near the 
affected keratinocytes which are thought to be involved in the pathogenesis of the lesions, 
appeared normal. Similar mitochondrial changes in granular cells have been described in 
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progressive symmetric erthrokeratodermia which also has palmoplantar involvement 
(Nazzaro, 1986 as cited by Hull, 1986). 
 
 
1.2.4. Age of onset  
The age of onset varies from infancy to early adulthood and severity varies with the age of 
onset (Findlay et al., 1977; Hull, 1986). Most individuals show symptoms by the age of five 
and in severe cases, the disorder manifests in infancy (Hull, 1986). The condition improves 
with age and in adulthood, minimal or no scaling may be noted although there is 
considerable inter-individual variation (Findlay and Morrison, 1978; Findlay et al., 1977).  
 
 
1.2.5. Aggravating factors and improvement 
Symptoms often worsen in winter with the onset of the recurrent peeling generally starting 
with the onset of the cold season (March or April in South Africa) and subsiding as the 
weather becomes warmer (August – October, varies through the years based on the climate) 
(Findlay et al., 1977). In more severe cases, symptoms persist all year round (Findlay et al., 
1977; Hull, 1986). Additionally, low humidity has also been associated with more severe 
lesions as individuals who have relocated to high humidity regions have reported 
improvement (Hull, 1986). Menstruation has also been reported as an aggravating factor in 
women whereas pregnancy drastically improves or eradicates symptoms for the duration of 
the pregnancy (Hull, 1986). Other aggravating factors include moisture, general anaesthesia, 
infections (particularly upper respiratory tract infections), antibiotics and topical steroids 
(Findlay and Morrison, 1978; Findlay et al., 1977; Hull, 1986; Ngcungcu et al., 2017).  
 
 
1.2.6. Genetics of KWE 
1.2.6.1. Mode of inheritance and penetrance 
KWE is a highly penetrant, autosomal dominant disorder (Findlay and Morrison, 1978). The 
penetrance has been estimated from 85% (Findlay et al., 1977) to 92.6 % (Hull, 1986); 
although these figures may underestimate the true penetrance of KWE. Disease expressivity 
varies even within families and often subsides in adulthood. These factors may affect 
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penetrance if individuals are incorrectly diagnosed when the disease has improved or if 
individuals have very mild symptoms. 
 
 
1.2.6.2. Prevalence 
KWE is very rare across the world but relatively common in the white and Coloured Afrikaner 
populations of South Africa.  Based on the known KWE families and the use of the 1980 
South African census data, the prevalence of KWE was estimated at 1/13 307 among all 
South African whites, 1/7 208 among white Afrikaners (accounted for 54% of the white 
population at the time) and 1/90 483 among the Coloured population (Hull, 1986). KWE has 
been reported in a German family (Starfield et al., 1997), two Norwegian families (Ngcungcu 
et al., 2017), the USA (in a family of Norwegian descent) (Huntington and Jassim, 2006), in 
the UK (in a family linked to the South African pedigrees) and a spontaneous case in 
Denmark (Danielsen et al., 2001, Starfield et al., 1997, Hull, 1986). There is now an extensive 
African diaspora of cases across the world (Hull, personal communication). 
 
 
Genetic drift by founder effect is the cause of the high prevalence of KWE in South African 
Afrikaners as all KWE families in South Africa can be traced back to a common ancestor, 
Captain Francois Renier Duminy, originally from France, who is thought to be the founder 
(Hull, 1986). Linkage studies in the German, Norwegian and Danish patients suggest that the 
causal mutations in these populations have a different origin from the South African founder 
mutation (Danielsen et al., 2001; Ngcungcu et al., 2017; Starfield et al., 1997). 
 
 
1.2.7. Identification of the position of the KWE locus 
Repetitive DNA, particularly short tandem repeat (STR) or microsatellites, are highly 
polymorphic markers dispersed across the genome that can be leveraged to identify regions 
linked to a disease by linkage analysis, thereby identifying the genetic region containing  the 
causal mutation for a Mendelian disease. Linkage relies on the idea that markers and/or 
genes that lie in close proximity to each other on a chromosome will remain close to each 
other during meiosis without recombination happening between these markers (Pulst, 
1999). Therefore, if a given microsatellite profile or haplotype is observed at a significantly 
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higher frequency in affected individuals, the disease mutation is close to those markers. A 
lod score (likelihood of linkage of given marker to disease) is calculated using different 
recombination fractions to get the maximum likelihood of linkage estimate for the 
recombination fraction at the highest lod score observed, with a lod score of 3.0 or higher 
considered as evidence for linkage and a lod score of -2 considered as evidence against 
linkage (Pulst, 1999). This analysis also takes into account the mode of inheritance and the 
penetrance of the trait. The same analysis can be performed using SNP markers. 
 
 
Using microsatellite linkage analysis, the first major breakthrough in KWE genetics was the 
localisation of the KWE locus to the short arm of chromosome 8. Through linkage analysis, 
Starfield et al. (1997) the causative mutation was localised to chromosome 8p22-p23, 
between and including markers D8S550 and D8S552 (later refined to D8S550 and D8S1759 
(Appel et al., 2002)), also known as the KWE critical region. The KWE critical region is a large 
(approximately 1.2 Mb), complex region with many genes. The region is flanked by two 
olfactory repeat regions which are prone to non-homologous recombination which results in 
chromosome rearrangements, including a common 4.7 Mb polymorphic 8p23 inversion 
(Giglio et al., 2002). The region has also been associated with certain forms of cancer such as 
prostate cancer (MacGrogan et al., 1994 as cited by Giglio et al., 2002). A common haplotype 
within the KWE critical region was identified in affected South African families, and therefore 
a single mutation is expected to be causal across all the South African families (Starfield et 
al., 1997). A different haplotype was identified within the same region in the German family 
suggesting tht the German mutations in the KWE critical region but is likely to be different 
from the South African mutation (Starfield et al., 1997). 
 
 
1.2.8. Exclusion of genes in the KWE critical region 
Since the localisation of the KWE mutation to the KWE critical region, a number of studies 
have interrogated the coding regions within the KWE critical region. Appel et al. (2002) 
investigated the KWE critical region by cloning and sequencing a large part of the region. 
Twelve transcripts were identified in the region using exome trapping but no pathogenic 
variants were identified in any of the coding regions (Appel et al., 2002).  
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Hobbs and colleagues (2012) several genes as candidate genes due to their roles in 
keratinocyte differentiation or maintenance of the skin’s integrity. The coding regions, 
intron/exon junctions, and UTRs of cathepsin B (CTSB) and farnesyl-diphosphate 
farnesyltransferase (FDFT1), C8orf49 and the deubiquitinating enzyme 3 (DUB-3) were 
sequenced (Hobbs, MSc dissertation 2008). Additionally, gene expression studies of two of 
the most biologically relevant genes within the region, CTSB and FDFT1, were done (Hobbs 
et al., 2012). No causal mutation was identified in any of the sequenced genes and these 
genes were excluded as candidate genes for KWE. After analysing gene expression levels, 
FDFT1 showed higher expression levels in affected individuals, although this result was not 
significant (Hobbs et al., 2012).  
 
 
Using a custom tiling array covering the KWE critical region, Hull et al. interrogated the CNVs 
in the critical region using 385,000 probes to cover the region (Hull et al., 2013). No CNVs 
were found for any of the genes within the region and several small non-coding CNVs were 
identified in the region but none of the identified CNVs appeared to have a role in KWE (Hull 
et al., 2013). Interestingly, a duplication upstream the CTSB gene was found in 3/5 patients 
but not in any of the controls. The authors noted that the variant may regulate CTSB 
expression or may also affect other genes in the region. Another CNV upstream DUB3 was 
identified in 3/5 patients and was thought to regulate DUB3. The authors did not pursue 
these two variants any further after the study.  
 
 
The KWE mutation therefore remained elusive, even after the interrogation of the most 
likely genes in the region and after assessing the CNVs in the region. The failure to identify 
the KWE causal mutation was due to a number of reasons including the fact that it could 
have been in a non-coding region, since this was not investigated, and it could have been 
missed due to technical factors which meant that it was not detected in all affected 
individuals. Alternatively, although very unlikely (high linkage score in the linkage study 
(Starfield et al., 1997), the mutation may not within KWE critical region. KWE shows 
incomplete penetrance and therefore some patients may have been designated as not 
having the disease which would lead to the exclusion of mutations found in these 
individuals. Although CNV analysis and expression studies have been carried out, the 
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methods that were used to interrogate the KWE critical region and gene expression may 
have not been sensitive enough to detect the mutation. 
 
 
1.3. Alternative mutation finding strategies 
Since previous attempts to identify the mutation responsible for KWE were unsuccessful and 
included candidate gene sequencing of a single or a few genes, a new approach was 
required. With advances in technology, we are now able to sequence chromosome regions, 
whole exomes and even whole genomes using next generation sequencing (NGS). NGS has 
become an essential tool in disease gene identification as it allows for massively parallel 
sequencing at high speed and a lower per base cost (Ari and Arikan, 2016). Whole genome 
sequencing, targeted capture resequencing and exome sequencing strategies have been 
used in several studies to determine the causative mutations for a range of Mendelian 
disorders, mainly for autosomal recessive traits, but also for inherited autosomal dominant 
disorders. Most of the causal variants discovered using NGS have been small variants within 
the coding region of a gene. With the appropriate bioinformatics analysis, NGS sequencing 
can successfully detect small variants as well as large structural variants, including copy 
number variants. 
 
 
1.3.1. Copy number variation 
Copy number variants (CNVs) are defined as DNA segments that are 1 kb or more and are 
present in variable copy numbers when compared to the reference genome (Redon et al., 
2006). They are spread across the genome, accounts for about 12% of the human genome, 
and have been shown to be associated with at least 3000 genes (Kehrer-Sawatzki, 2007). 
CNVs are found in both gene coding and non-coding regions of the genome, including 
regions that overlap with regulatory elements. They contribute to genomic diversity, which 
can result in phenotypic diversity (Kehrer-Sawatzki, 2007). CNVs may have dramatic 
phenotypic consequences if they change gene dosage, disrupt genes to make them non-
functional or interfere with long range gene regulation, thus influencing gene expression. For 
instance, if a gene suppressor is deleted or an activator binding site is duplicated, then the 
transcription of the gene regulated by these sites may increase, whereas if an activator 
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binding site is deleted then the gene may not be expressed or its transcription will be 
reduced, depending on the importance of the activator in initiation of transcription.  
 
 
Like all other genetic variants, CNVs may have medical significance with 14.5% of all 
characterised CNVs overlapping with OMIM morbid genes (Redon et al., 2006). CNVs have 
been found to be polymorphic in breakpoints of DiGeorge and Williams Beuren syndromes 
(Redon et al., 2006). CNVs have also been implicated in microdeletion and duplication 
disorders and have been shown to confer risk to complex disease traits such as HIV infection, 
where low copy number of the CCL3L1 gene makes the person more susceptible to HIV, and 
the DEFB4 gene that predisposes individuals to Crohn’s  disease (Kehrer-Sawatzki, 2007; 
Redon et al., 2006).  
 
 
CNVs may also overlap with regulatory elements such as enhancers and repressors which are 
often found in the non-coding regions of the genome. Copy number variation of these 
elements has been shown to alter phenotypes. Duplications of non-coding regulatory 
regions are an uncommon disease mechanism but enhancer duplications have been 
previously described, primarily in limb malformation disorders and some sex reversal 
phenotypes (Dathe et al., 2009; Klopocki et al., 2011; Lohan et al., 2014). Polydactylies and 
syndactylies, including Hass-type polysyndactyly (HTS) (larger duplication), Laurin-Sandrow 
syndrome (LSS) and brachydactyly type A2 (BDA2), are caused by duplications of enhancers 
in noncoding regions (Dathe et al., 2009; Lohan et al., 2014).  
 
 
SNP genotyping arrays and comparative genomic hybridization arrays can be used for CNV 
detection. NGS can also be used to detect CNVs but because NGS methods have short reads 
(75-150 bp depending on the assay) the usual analysis strategies may not be able to easily 
detect large CNV. NGS can however be used to detect evidence of CNV through split reads, 
for example where a read has two parts of the genome close to each other that are usually 
far apart in the genome suggesting the presence of a deletion or duplication. Conventional 
NGS analysis tools such as GATK may miss CNVs so alternative alignment and variant calling 
tools should be considered when looking for CNVs.  
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1.3.2. Targeted capture resequencing of the KWE critical region 
To date, all studies that have searched for the KWE mutation have focused on genes or 
coding regions (exons) of genes within the KWE critical region and all have failed to identify 
the mutation that causes KWE. The KWE mutation may therefore, not be in a gene or coding 
region, but in a non-coding region such as an intron or an intergenic region. By sequencing 
the entire KWE critical region on chromosome 8 (8p23.1-p22) using target-capture of the 
KWE critical region, all DNA sequence differences between affected and unaffected 
individuals could be identified and all variants within the KWE critical region including single 
nucleotide variants (SNVs), insertions and deletions (indels) and CNVs could be detected. 
Mutations within coding, regulatory, intronic and intergenic regions will be detected and can 
be compared between affected and unaffected individuals to identify mutations unique to 
KWE affected individuals. By sequencing the entire KWE critical region, the KWE causal 
mutation should be identified if it is indeed in this region and is detectable given the 
limitations of the approach. Whole genome sequence approaches should also detect the 
same mutations in this region but performing targeted capture resequencing of the KWE 
critical region is more cost effect and would yield more accurate due to the high coverage 
that is possible with targeted capture resequencing (Dapprich et al., 2016).  
 
 
1.3.3.  Exome sequencing  
A vast majority of all pathogenic mutations in monogenic disorders are located in the exons 
(Takeichi et al., 2013). The first exome sequencing study used to identify the causal mutation 
for a Mendelian disorder was published in 2010. In this study, mutations in the DHODH gene 
were shown to be responsible for Miller syndrome (Ng et al., 2010). Exome sequencing has 
identified causal mutations for several skin disorders that are caused by de novo and 
recessive mutations (Takeichi et al., 2013). Through several studies, exome sequencing has 
also been shown to be very successful in identifying causal mutations for dominant traits. 
Although exome sequencing has been successful in identifying disease genes in inherited 
disorders, the identification procedures and analyses are also complicated and as a result, 
pathogenic variants may be missed in some studies. Examples of the successful identification 
of causal genes for dominant traits include the identification of mutations in the CARD14 
gene responsible for autosomal dominant psoriasis susceptibility locus 2 (PSORS2) (Jordan et 
al., 2012) and the identification of LMX1B mutation involved in focal segmental 
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glomerulosclerosis (FSGS, also autosomal dominant) (Boyer et al., 2013). Exome sequencing 
uses a capture design which allows for sequencing of exons and 3’ and 5’ untranslated 
regions (UTRs) of all known genes. Some genes are regulatory genes (e.g. transcription 
factors) and mutations in these regulatory genes may affect regulation of target genes.  
 
 
1.4. Genome structure and gene regulation 
The genome is a complex structure regulated by chromatin folding and several epigenetic 
mechanisms including histone modifications, DNA methylation and micro-RNAs (Costa, 2008; 
Steiner et al., 2016). It is comprised of DNA wrapped around histones forming the 
nucleosomes that are densely compacted in a tightly regulated spatial manner to form 
chromatin. The nucleosome is made of 147bp DNA wrapped over 1.65 turns around 
nucleosomes (four pairs of core histones) (Luger et al., 1997; Radman-Livaja and Rando, 
2010). The core histones, namely H2A, H2B, H3 and H4 (Lu et al., 2006), are charged. H2A 
and H2B have positive charges (due to lysines at the C-terminus) and the other two have 
negative charges (Latchman, 2005). These charges determine how tightly bound the DNA is 
to the histones and since DNA is negatively charged, it associates with the positively charged 
histones. Each of the core histones has 2 subunits (Lu et al., 2006). The H1 histones maintain 
the structure of the nucleosome by clamping DNA to the core proteins to prevent DNA 
movement away from the core histones (Luger et al., 1997). Several histone modifications 
influence chromatin conformation and the regulation of gene expression. These alterations 
determine the level of DNA binding to the histones (Lu et al., 2006). When the DNA is free 
from the nucleosomes and in a more open configuration, it becomes available for binding of 
transcription factors and hence gene transcription.  
 
 
1.4.1. Histone modifications 
Several mechanisms that alter histones and influence gene regulation are acetylation, 
methylation and phosphorylation (Lu et al., 2006), and have been described and evaluated in 
the ENCODE project (Table 1.2). These histone modifications and the DNA it is associated 
with can be detected using Chromatin Immunoprecipitation Sequencing (ChIP-Seq) which 
uses an antibody specific to that histone modification to detect the DNA fragments that 
associate with that particular histone modification (Landt et al., 2012). The modifications can 
26 
 
be used to determine the chromatin state and the presence of regulatory elements including 
enhancers, insulators, promoters, gene bodies and inactive sites, just to name a few. Only 
histone acetylation will be discussed because it will be referred to again in the subsequent 
chapters.  
 
Table 1.2: Histone modifications and variations used in the ENCODE project to access the 
genome for regulatory elements* 
Histone 
modification Putative functions 
H2A.Z 
Histone protein variant (H2A.Z) associated with regulatory elements with 
dynamic chromatin 
H3K4me1 
Mark of regulatory elements associated with enhancers and other distal 
elements, but  also enriched downstream of transcription starts 
H3K4me2 Mark of regulatory elements associated with promoters and enhancers 
H3K4me3 
Mark of regulatory elements primarily associated with 
promoters/transcription starts 
H3K9ac Mark of active regulatory elements with preference for promoters 
H3K9me1 Preference for the 5’ end of genes 
H3K9me3 
Repressive mark associated with constitutive heterochromatin and 
repetitive elements 
H3K27ac 
Mark of active regulatory elements; may distinguish active enhancers and 
promoters from their inactive counterparts 
H3K27me3 
Repressive mark established by polycomb complex activity associated with 
repressive domains and silent developmental genes 
H3K36me3 
Elongation mark associated with transcribed portions of genes, with 
preference for 3’ regions after intron 1 
H3K79me2 Transcription-associated mark, with preference for 5’ end of genes 
H4K20me1 Preference for 5’ end of genes 
*(ENCODE Project Consortium, 2012) 
    
 
Histone acetyltransferases (HATs) and histone de-acetyltransferases (HDACs) are histone 
acetylation and deacetylation enzymes, respectively, that are involved in nucleosome folding 
and determine gene expression by exposing or compacting DNA (Mercurio et al., 2010). 
HATs acetylate the lysine groups in positively charged histones to reduce the positive charge 
in the protein thus reducing the association between the positively charged protein and 
negatively charged DNA (Latchman, 2005). This mechanism also decreases the binding 
affinity of H1 allowing the DNA to dissociate from the histones to allow transcription factors 
to bind to allow gene expression (Latchman, 2005). This modification is associated with open 
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chromatin near regulatory regions, including active enhancers. Histone mark, H3K27ac 
associates with active enhancer elements and this modification is often cell specific 
(Creyghton et al., 2010). Histone acetylation can be reversed by HDACs which remove the 
acetyl group, increasing the positive charge of the protein thus attracting the DNA back to 
the histones and inhibiting gene expression (Latchman, 2005). Epigenetic errors can occur 
during histone modification and as a result can lead to the activation or suppression of gene 
expression depending on the nature and histone modifying enzyme causing the errors. 
Errors could happen during histone acetylation and histone deacetylation with the HAT and 
HDAC enzymes regulating the mechanisms, respectively (Mercurio et al., 2010).  
 
 
1.4.2. Gene regulation through chromatin structure 
Gene expression is highly regulated by chromatin conformation and looping  which 
determines how parts of the genome are accessible to each other and are therefore able to 
interact. This is achieved through highly conserved topologically associating domains (TADs) 
which can be identified using different chromatin conformation capture technologies such as 
4C, 5C, Hi-C, CaptureC and ChIA-PET (Lupiáñez et al., 2016). TADs are defined as linear, 
discrete genomic units that loop into three-dimensional (3D) structures that bring together 
regions of the genome which are usually far from each other and favours chromatin 
interactions internally within the loop and discourage interactions with regions outside the 
loop (Ciabrelli and Cavalli, 2015; Lupiáñez et al., 2016). The looping allows for protein 
mediated interactions between enhancers and promoters to occur, thus allowing for the 
activation of transcription (Lupiáñez et al., 2016).  The boundaries of TADs have insulators 
(Ciabrelli and Cavalli, 2015) and are demarcated are by CCTC-binding factor (CTCF) binding. 
CTCF is a multifunctional protein essential in gene regulation that acts as a transcription 
regulator by acting on promoters and facilitating long range chromatin interactions (Steiner 
et al., 2016). When TADs are altered, gene regulation may also be altered as enhancers can 
either be blocked off from their target genes or be placed in the close proximity to non-
target genes resulting in mis-expression or enhancer adoption (Lupiáñez et al., 2015; 
Spielmann and Mundlos, 2013).   
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1.5. Aim and Objectives  
The aim of this study was to identify and characterize the causal mutation for keratolytic 
winter erythema (KWE) in South African families. 
 
Objectives  
1. To use a NGS approach to search for the KWE mutation: target-capture followed by 
NGS of the 8p KWE critical region applying a variant filtering process for possible 
candidate causative mutations including the following criteria: mode of inheritance, 
segregation with affection status, mutation frequency, functional impact or biological 
relevance, and modelling for incomplete penetrance. 
2. To validate potential causal variants by PCR and Sanger sequencing in additional KWE 
families.  
3. To perform functional studies to determine the biological impact of validated 
potential causal variants in skin tissue from cases and unaffected controls.  
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Chapter 2 
 
Materials and Methods 
 
2.1. Participants 
A total of 167 samples from affected and control Afrikaner individuals were included in this 
study and the disease status of these individuals is summarized in Table 2.1. Forty-two 
individuals, including 23 affected individuals and 19 unaffected individuals, from three KWE 
families (A, B and C, Figure 2.1) and a singleton from a different KWE family (Family E: III-4, 
Figure 2.2) were sequenced. An additional seven random white Afrikaners, not related to 
individuals in the study were included in the targeted resequencing as unrelated, ethnically 
matched controls (samples provided by the NHLS, Division of Human Genetics). For the 
validation studies, the 49 sequenced individuals (including the 7 random controls) and 23 
additional KWE family members from 4 families (11 affected and 12 unaffected individuals 
from families D, E, F and G, Figure 2.2) and 89 unaffected and unrelated ethnically matched 
controls were used. A nuclear family from a larger KWE family comprising of an affected 
mother and her two sons was used for the functional experiments (Family H: I-2, II-1 and II-2, 
Figure 2.2).  
 
Table 2.1: Participants used in the study shown according to the different experiments 
KWE Family Affected Not 
Affected 
8p23.1-22 
sequencing 
Validation Functional 
studies 
A, B and C 23 19 All All None 
D, E, F and G 11 12 None All None 
H 3 0 None 2 All 
C
o
n
tr
o
ls
 DNA only 0 89 None All None 
Biopsy only 3 0 None None Yes 
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Figure 2.1: Pedigrees of South African KWE families used for next generation sequencing 
The individuals whose samples were subjected to NGS sequencing are marked with an asterisk (*).  
    Family A 
  Family B      Family C 
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Figure 2.2: Pedigrees used for the validation of potential causal variants identified using NGS and for functional analysis 
The individuals whose samples were used for validation are marked by an asterisk (*). Individuals marked with a hash tag (#) indicate 
individuals that were included in NGS sequencing. Family H was also used for the functional studies. 
Family D  Family E 
  Family F Family G      Family H 
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All DNA samples (except Family H) and phenotype data were collected with informed 
consent prior to the present study, as part of the ongoing studies (1985-2007) in the Division 
of Human Genetics (HREC Protocol numbers: M050706 and M070423). Next generation 
sequencing was carried out under an existing protocol approved by the HREC (Protocol 
number: M070423) but amended and extended to allow for next generation sequencing in 
Switzerland. The use of existing data/samples and the collection of new data/ samples 
(Family H) for this PhD project were approved by the HREC (Protocol number: M140530, 
Appendix A). Export permits were granted by the South African Department of Health to 
transport samples to Novartis (Basel, Switzerland) for sequencing, Haukeland University 
Hospital (Bergen, Norway) and Radboud University Medical Center (Nijmegen, The 
Netherlands) for qPCR and immunohistochemistry, respectively. Materials transfer 
agreements were signed by both the senders and recipients.  
 
 
2.2.  Laboratory methods 
The project had three major methodological components, namely: next generation 
sequencing; analysis and validation of NGS results; in silico and in vitro functional analysis. 
Figure 2.3 summarizes the different experiments conducted and the analyses performed.  
 
 
2.2.1.  DNA extraction 
The DNA used for the NGS portion of the study was already available for this study, it had 
been extracted from blood using the salting out method (Miller et al., 1988). The DNA from 
the two affected sons from family H was extracted from brush buccal swab samples using 
the Gentra Puregene DNA purification kit (Appendix B). DNA quality was determined by 
running DNA samples on a 0.8% agarose gel and all degraded samples were excluded from 
the study. DNA was quantified using the Nanodrop® ND-1000 Spectrophotometer 
(Nanodrop Technologies, Wilmington, DE, USA) and normalized to 100 ng/µl with 1X Tris 
Ethylenediaminetetraacetic acid (TE) buffer (salting out DNA) or Hydration buffer (buccal 
swab samples) and stored at 4°C. Additionally, the DNA used for the NGS experiments was 
also quantified using the Qubit to determine the concentration of double stranded DNA and 
normalised to 1µg (targeted capture) using TE buffer.  
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Figure 2.3: High level view of the workflow followed to identify, validate and characterize 
the KWE mutation. 
In vitro functional analysis 
-Family H 
- 3 affected individuals 
-3 ethnically matched controls 
Next Generation Sequencing 
8p23-p22 target capture 
- 42 Individuals from KWE families 
and 7 ethnically matched 
Afrikaner controls 
- 23 affected and 26 unaffected 
Variant discovery and genotyping  
- GATK 
- SNPs and Indels 
Variant filtering 
Variant discovery and genotyping  
- Pindel  
- Structural variants 
Variant Annotation 
KWE causal variant identification 
Experimental Variant validation 
In silico functional analysis 
 
Confirmation of causal variant in 
affected individuals 
Analysis 
-Up/down regulation of gene and 
protein in affects vs. unaffected 
qPCR of genes possibly affected by 
the mutation 
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2.2.2.  Next generation sequencing using targeted resequencing 
A microgram (1µg) of DNA was fragmented by shearing using the single tube method on the 
Covaris E210 Water Bath Sonicator  (Covaris Inc., Woburn, Massachusetts, USA). Fragmented 
DNA was anayled using the Agilent Bioanlyser  to determine fragment size (target ~700bp, 
sample was repeated if fragments were significantly smaller). The resulting fragments were 
repaired to remove overhangs to produce blunt 5’ ends and the 3’ ends of the fragments 
were adenylated (single A). A ligation step ligated adapter sequences to the ends of each 
fragment which enabled the DNA to bind to the sequencing flow cell. The adapter sequences 
also contained bases complementary to the sequencing primers used in the sequencing step. 
Index sequences were also ligated and used as identifiers for each sample. A number of 
clean-up steps removed non-ligated fragments which were then enriched for by PCR and 
followed by appropriate clean-up steps as per protocol. In this reaction, the PCR primers 
annealed to the ends of the adapters on either side of the ligated fragments and only 
fragments with adapters on both sides will be amplified. The products were used to assess 
the quality of the fragments by means of the appropriate Agilent DNA chips. Where the 
ligated libraries met quality control measures, libraries were stored for the KWE critical 
region DNA capture.  
 
 
To enrich specifically for the KWE critical region, DNA libraries were prepared with the 
Illumina TruSeq DNA Sample preparation kit v.2 (#FC-121-2001, Illumina Inc.,San Diego, CA, 
USA) and the target region (KWE critical region: hg19 build, chr8:11 477 641-12 742 458) was 
captured following the NimbleGen SeqCap EZ SR protocol (#6266304001, Roche NimbleGen, 
Madison, WI, USA). The NimbleGen SeqCap EZ library was designed to have primers that 
span the KWE critical region. The kit contained biotinylated long oligonucleotide probes in 
redundant tiling manner with up to 38X base coverage specific to the target region. The 
libraries were sequenced on the Illumina HiSeq 2000 following a 101 bp paired-end 
sequencing protocol. Libraries were pooled so that each lane had eight libraries from eight 
samples. 
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2.3.  Processing of NGS data 
Illumina sequencers generate the sequencing output as per-cycle BCL base call files that are 
not compatible with many downstream processing protocols. These BCL files were combined 
and converted into FASTQ files which are compatible with downstream processing using 
bcl2fastq. 
 
 
The sequencing data generation and quality control (QC) check was conducted on FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to generate a QC report. 
FastQC assesses the sequence quality, read length, GC content, overexpressed sequences 
and sequence duplication. Runs were considered to be of good quality when the 25th 
percentile Phred score (which determines the probability of each base being called correctly) 
of all bases was above Q26. If the 25th percentile Phred score for more than one third of the 
bases were below Q20 then the data were considered to be of low quality, were analysed 
with caution, and flagged for a repeat experiment to generate new data. The flow cell quality 
traces for “per base sequence quality” are shown in Appendix C.  
 
 
2.4.  Small variant calls using the GATK pipeline 
If the run quality was acceptable, the raw sequencing data was processed to prepare a data 
set for analysis (Figure 2.4). This was done in a preprocessing step, followed by a variant 
discovery step. Picard tools and the Genome Analysis Toolkit (GATK) (DePristo et al., 2011; 
McKenna et al., 2010) were used to process the data except where noted 
(http://www.broadinstitute.org/gatk/guide/topic?name=best-practices).  
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Figure 2.4: GATK workflow for data NGS data processing and small variant calling. 
(Adapted from http://gatkforums.broadinstitute.org/gatk/discussion/1186/old-version-of-
best-practices-from-gatk-2-0-retired) 
 
 
2.4.1.  Pre-processing 
The sequencing output results in millions of reads that are in FASTQ format that have 
Illumina adapter sequences at the 3’ and 5’ end and indexes to identify the reads. Some of 
these reads are of low quality. The adaptors and the low quality reads were removed using 
FASTQC and the resulting files were in FastQC format. The reads were mapped to the human 
genome (hg19) using Burrows-Wheeler Aligner (BWA) (Li and Durbin, 2009). The BAM files 
created by BWA were then sorted and indexed using SAMtools (Li et al., 2009). Duplicated 
reads were identified, marked as duplicates and removed using Picard tools 
(https://broadinstitute.github.io/picard/). The resulting de-duplicated reads were also 
sorted and indexed. All subsequent processes were done on GATK. Using the 
IndelTargetCreator, possible true indels assigned as mismatches by BWA were identified and 
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re-aligned using the IndelRealigner. This was followed by the recalibration and scoring of 
variants by the BaseRecalibrator. The final output of the pre-processing steps was analysis-
ready reads in the form of recalibrated BAM files that were interrogated in the variant 
discovery process. 
 
 
2.4.2.  Variant calling 
The GATK UnifiedGenotyper module was used for variant calling to identify sites that were 
different from the reference sequence thereby identifying single nucleotide variants (SNVs) 
and indels. A minimum base quality score of 20 was used as a cut-off. The UnifiedGenotyper 
module uses a Bayesian genotype likelihood model to estimate the most likely genotypes 
and allele frequencies for each position in the sequenced samples. The module then outputs 
a genotype for each base for every sample or only outputs the variant sites, based on the 
user preferences. The module uses analysis-ready reads from the pre-processing steps and 
outputs raw, unfiltered, highly sensitive variants. Variant quality recalibration uses machine 
learning to determine good and bad variants then annotates genotypes taking into account 
external data such as known genotypes (e.g. 1000 Genomes Project data (The 1000 
Genomes Project Consortium, 2015)) and rescores genotypes based on read coverage and 
orientation producing a recalibrated VCF file.  The VCF file was then processed for genotype 
refinement to improve genotype call accuracy and filter out low confidence genotype calls 
resulting in a refined VCF file containing analysis ready variants.  VCFs were loaded onto the 
Vertica Analytic Database which is a commercial structured query language (SQL) relational 
database system (Lamb et al., 2012). All the variant filtering was performed using SQL 
queries on this database and additional queries were run on Postgres (open source) when 
Vertica was not available. 
 
 
2.4.3.  Variant annotation 
Known and novel variant status was assigned based on comparison to publicly available data 
(such as dbSNP, the 1000 Genomes Project, and NHLBI Exome Sequencing Project (ESP)) and 
in-house Novartis sequence data. The Ensembl Variant Effect Predictor (VEP) tool was used 
to determine the position of each variant in exons, introns, intergenic regions or within 
regulatory regions (McLaren et al., 2016). This tool assesses potential functional impact (e.g. 
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deleterious variants) or the biological relevance of the mutations. Non-synonymous variants, 
synonymous, splice variants and regulatory variants were prioritized as potential causal 
variants. 
 
 
2.4.4.  Variant Filtering 
The following criteria were applied to identify the causal variant: (1) within the KWE critical 
region; (2) segregate with disease across all three families following an autosomal dominant 
mode of inheritance; (3) novel; and (4) alter a protein’s amino acid sequence and be likely to 
disrupt the function of that protein.  Incomplete penetrance was accounted for in step 2, 
and possible causal variants were considered even if they were present in a maximum of two 
unaffected family members with an affected parent, child and/or sibling, assuming 90% 
penetrance. Variants present in a minimum of 80% of the affected group but not in the 
unaffected group were also considered, accounting for possible incorrect affected status. 
Non-coding variants were also considered, following criteria 1-3.  
 
 
2.5.  Structural variant calling using Pindel 
BWA was used to align the reads using the "mem" method. The BAM files resulting from the 
alignment were passed through the version of Pindel (Ye et al., 2009) downloaded from the 
Pindel github site (https://github.com/genome/pindel) (Appendix D). The results were 
parsed into individual components for each structural variant. These components were 
loaded into a relational database which included de-identified information about each 
participant. Simple SQL queries were used against the database that counted the number of 
times each variant occurred, grouped by disease status.  For variant filtering, the sample 
filtrating protocol as outlined in section 2.4.4 was used.  
 
 
2.6.  Validation of potential causal variants 
Sequence data interpretation may lead to incorrect genotyping calls and therefore as an 
additional quality control step, the potential causal variant was validated in all sequenced 
individuals (n=49, shown in Figure 2.2 and including seven unrelated ethnically matched 
controls). An additional four KWE families (including 11 affected and 12 unaffected 
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individuals) and 89 ethnically matched controls (random Afrikaners with no history of KWE) 
were used for validation.  Samples used in the functional studies were also validated for the 
causal variant (Figure 2.2). Because the disorder is an autosomal dominant disorder, one 
variant that is unique to all affected individuals was expected to remain after validation. A 
tandem duplication that segregates with KWE was validated using PCR and Sanger 
sequencing. Primer design, PCR essay and condition and sequencing protocol are outlined in 
appendix E. 
 
 
2.7.  In silico functional analysis 
Published data from various sources such as ENCODE (ENCODE Project Consortium, 2012) 
and the Epigenome project (Kundaje et al., 2015; Zhu et al., 2013) were used to perform the 
in silico functional analysis. Where possible, data from keratinocytes or from a keratinocyte 
cell line were used. In the absence of keratinocyte data, data from other cells types were 
used. All the data in this section, unless otherwise stated was retrieved using ENCODE data 
(ENCODE Project Consortium, 2012) and visualised using the UCSC genome browser (Kent et 
al., 2002). 
 
 
2.7.1.  Frequency of structural variants and overlapping regulatory elements 
The frequency and novelty of large structural variants was evaluated through DGV 
(MacDonald et al., 2014) which annotates known structural variants from literature and 
databases, such as the 1000 Genomes Project. Variants that were present in DGV were 
excluded from further analysis. Large structural variants were also assessed through UCSC 
genome browser using ENCODE data to determine if variants overlapped with any regulatory 
regions.  
 
 
2.7.2.  Identification of regulatory elements that overlap with the causal variant 
At the first pass, all “Regulation” tracks were activated, so that all regulatory features that 
overlap with the structural variants could be detected. Additionally, transcription factor 
binding sites overlapping with the regulatory element within the KWE causal mutation  were 
identified from the ENCODE factorbook ChIP-seq data (Wang et al., 2013). ENCODE 
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factorbook ChIP-seq experimentally interrogated the binding of 167 transcription factors 
across several cell lines in 837 experiments. 
 
 
2.7.3.  Genomic architecture prediction 
The genomic architecture of the region containing the duplication was evaluated using 
available Hi-C and ChIP-seq data (Rao et al., 2014). The potential pathogenic effect of the 
identified mutation may depend on the topological domain structure of the genomic region. 
Domain demarcations are defined by CTCF binding and these are conserved between cell 
types.  CTCF binding sites around the identified mutation were determined in normal human 
epidermal keratinocytes (NHEK) and in a breast cancer cell line (MCF-7) using CTCF ChIP-seq 
data. Like the NHEKs, the MCF-7 cell line is of ectodermal origin   and was therefore used in 
the absence of keratinocyte data. The MCF-7 cell line was used to determine the genomic 
architecture around the identified mutation using CTCF chromatin interaction data from 
Chromatin Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET)(Li et al., 2010) as 
no CTCF interaction data exists for epidermal keratinocytes (ENCODE Project Consortium, 
2012). 
 
 
2.7.4.  Known regulatory element interactions 
RNA polymerase II (RNAPII)-targeted ChIA-PET interaction data was used to identify contacts 
between regulatory elements such as enhancers and promoters and to determine possible 
interactions between the regulatory elements and their predicted target genes. No RNAPII-
targeted ChIA-PET interaction data exists for epidermal keratinocytes; therefore all 
published RNAPII-targeted ChIA-PET interaction data from five cancer cell lines (breast 
cancer (MCF-7), chronic myeloid leukemia (K562), cervical cancer (HeLa-S3), colorectal 
cancer (HCT116) and promyelocytic (NB4) cell lines) were used to determine possible 
interactions. 
 
 
2.7.5. Epigenomic profiling using public databases  
Epigenomic data from ENCODE (ENCODE Project Consortium, 2012) and Epigenome 
Roadmap (Roadmap Epigenomics Consortium et al., 2015) project data were used to search 
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for regulatory elements and annotated non-coding variants. NHEK cell lines were prioritized 
as they are most similar to the cells affected in KWE. DNaseI-seq data from NHEK were used 
to identify DNaseI hypersensitive sites and define them as open chromatin could contain 
potential regulatory elements. The presence of regulatory elements in the regions of interest 
was further validated by integrating histone modification (H3K36me3/H3K27ac) data in 47 
different human cell types. The average H3K27ac signal across the duplicated regions was 
calculated to measure the overall regulatory activities of the structural variants, and the 
H3K36me3 signal across the gene body was calculated to measure the transcriptional 
activity of nearby genes. Assuming an enhancer’s activity will correlate with the expression 
of its regulated genes, Pearson correlations between H3K27ac signal of the tandem 
duplication and expression (H3K36me3) of nearby genes were calculated and used to predict 
the target gene/s of the tandem duplication as the nearby gene with the highest correlation. 
 
 
2.8.  In vitro functional analysis 
This portion of the study was done in collaboration with our Norwegian colleagues.  Samples 
were collected from South African (n=3 affected and n=3 controls) and Norwegian (n=3 
affected and n=3 controls) participants. Single 4 mm palmar skin punch biopsies were taken 
from affected individuals and ethnically matched healthy controls by a dermatologist. 
Biopsies were taken from the thenar region of the palm in regions that did not appear to be 
going through a peeling cycle (Figure 2.5). The biopsies were cut in two by a 
histopathologist, perpendicular to the skin surface. One half was used for relative qPCR 
expression studies and the other was processed for histology. Half of each biopsy was placed 
in 1ml dispase II protease (1.2 U/µl) for 4 hours to separate the epidermis from dermis. The 
epidermis was then placed in RNALater and stored at 4°C for 24 hours and then at -20°C until 
RNA extraction. The other half of the biopsy was placed in 10% formalin for 
immunohistochemistry processing.  
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Figure 2.5: Affected palm where the biopsy was taken 
The biopsy was taken from the thenar region of the hand where the skin did not appear to 
be going through a peeling cycle. (Image Credit: Prof Michele Ramsay) 
 
 
2.8.1.  Relative gene expression analysis 
The RNALater tubes containing the epidermis samples were thawed on ice. Each epidermis 
was homogenized using the TissueLyser II (Qiagen, Hilden, Germany) and total RNA was 
extracted using the RNeasy® kit (Qiagen, Hilden, Germany) as per manufactures instructions. 
RNA quality and quantity were determined using the Experion™ automated electrophoresis 
station  (Bio-Rad, Hercules, CA, USA) and the NanoDrop® ND-1000 spectrophotometer 
(Nanodrop Technologies, Wilmington, DE, USA) , respectively. One of the South African KWE 
samples was excluded from further analysis due to low RNA quality and concentration. 
Generation of first-strand cDNA was performed using the SuperScript® VILO™ cDNA 
Synthesis Kit (ThermoFisher Scientific, Waltham, MA, USA), with an input of 250ng of RNA 
per sample (along with a blank/negative control and a no reverse transcriptase control). The 
cDNA samples were then stored at -20°C.  
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The gene expression assays were run using 25ng cDNA and calibrator sample was used for 
each assay. The Applied Biosystems™ TaqMan® Gene Expression Assays (ThermoFisher 
Scientific, Waltham, MA, USA) for CTSB (Hs00947433_m1), FDFT1 (Hs00926054_m1), nei like 
DNA glycosylase 2 (NEIL2, Hs00979610h) and ribosomal protein lateral stalk subunit P0 
(RPLP0,Hs99999902m1, endogenous/ housekeeping gene control) were used to determine 
the gene expression levels of the respective genes. Although three housekeeping genes are 
usually recommended for normalisation (Bustin et al., 2010), RPLP0 was shown to be an 
appropriate and sufficient housekeeping gene in the epidermis as it’s expression was 
consistent during keratinocyte differentiation whereas the expression of commonly used 
housekeeping genes such as GAPDH altered with differentiation (Minner and Poumay, 2009).  
All the samples were run in triplicate on the on a 96 well plate using the ABI Prism 7900HT 
sequence detector system (Applied Biosystems, Foster City, CA, USA). The average threshold 
cycle (CT) values for each sample were used to determine gene expression using the ∆Ct-
method (Winer et al., 1999). Differences in gene expression levels between affected 
individuals and unaffected controls were determined, and P values were calculated by 
Mann-Whitney U test on R (R Development Core Team, 2008). All the protocols for RNA 
extraction, cDNA conversion and qPCR are shown in Appendix F. Reagent preparations 
protocols are listed in Appendix G. 
 
 
2.8.2.  Histology and immunohistochemistry 
On the samples were collected, biopsies were fixed in 10% buffered formalin for 4-8 hours 
immediately after collection then embedded in paraffin blocks before shipping from South 
Africa and Norway to our colleagues in The Netherlands. All histology and 
immunohistochemistry were done by Prof Joost Schalkwijk and his PhD student, Ivonne van 
Vlijmen-Willems. Paraffin sections were cut for histopathology (Haemotoxylin and Eosin 
(H&E) staining) and immunohistochemistry. Antisera against CTSB (R&D Systems), FDFT1 
(Sigma) and NEIL2 (Sigma) was used for immunohistochemistry. Antisera for CTSB, FDFT1 
and NEIL2 were raised in goat, rabbit and mouse respectively. Deparaffinized and 
dehydrated sections (6m) were pretreated for 10 minutes in 10 mM sodium citrate buffer, 
pH 6.0 for antigen retrieval. Endogenous peroxidase was blocked with 3% hydrogen 
peroxide. Background staining was reduced by using 5% normal serum of the animal in 
which the biotinylated conjugated serum was raised. Further staining and embedding was 
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according to standard protocols, using the avidin-biotin-peroxidase complex and amino-
ethyl-carbazole as a peroxidase substrate. CTSB staining was evaluated by two blinded 
observers.  CTSB staining intensity was scored on a scale from 0 to 3 points; 0 indicating no 
visible staining and 3 strong staining. Staining was scored separately for the stratum 
spinosum and the stratum granulosum. Scores for 7 patients and 7 controls were analyzed 
by a 2-tailed Mann Whitney U-test. 
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Chapter 3 
Results 
 
3.1. Coverage and small variant analysis 
Targeted capture sequencing of the KWE critical region on 8p23.1-22 was done in all 
members of the KWE related samples (n=42, 23 affected) and in seven unrelated, ethnically 
matched controls. The average read depth across the critical region was 795x and 92.3% of 
the target region was covered at >10x read depth.   
 
 
Small variant analysis was carried out in all sequenced individuals using Vertica. A total of 3 
690 rare or novel variants were found within the KWE critical region (variant present in at 
least one affected individual) and 410 of these variants were novel. No coding or regulatory 
small variants that segregated well with KWE were identified. However, a novel intronic 
variant in the FDFT1 gene located at chr8: 11 672 190 (C>T) was identified in all affected 
individuals but not in any of the unaffected individuals. The FDFT1 variant reference allele 
(C) is conserved in all primates but does not appear to overlap with any regulatory features 
in keratinocytes. There is no evidence to suggest that this variant causes KWE but it may be 
in linkage disequilibrium with the causal variant. 
 
 
3.2.  Structural variant analysis 
When no small variants were found to be the likely cause of KWE, structural variants were 
evaluated in the target capture sequencing data.  No structural variants overlapping with the 
coding regions within the KWE critical region segregated with the disease. From the target 
capture sequencing of the data, one variant, a tandem duplication within the KWE critical 
region was identified and showed strong segregation with KWE. This variant will be 
described in detail in the next section.  
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3.2.1.  A novel tandem duplication segregates with KWE 
A novel, non-coding 7.67 kb tandem duplication was identified in the KWE critical region on 
chr8:11 729 286-11 736 955 in 21/23 affected South African patients using the targeted 
sequencing data. Individuals with the tandem duplication had split reads that aligned to two 
parts of the genome, with the junction sequence of the duplication clearly defined in the 
reads (Figure 3.1). Pindel correctly identified the tandem duplication in 21/23 affected 
individuals but did not assign the tandem duplication to the remaining two affected 
individuals. Although the program did not detect the duplication in these two individuals, on 
manual inspection of the data they did have a small number of reads that suggested that 
they did in fact have the duplication, but had too few reads to be called with confidence by 
Pindel as having the mutation. Although the segregation of this variant was not perfect, it 
did show the best segregation pattern among the structural variants. 
 
 
3.2.2.  Validation of the tandem duplication 
Through validation, using PCR and Sanger sequencing (Figure 3.2), the tandem 
dupliacationwas confirmed in all affected individuals (23 sequenced individuals with KWE 
and 11 additional KWE affected individuals). This included the two individuals that were 
previously called by Pindel as not having the tandem duplication. The duplication was not 
detected in any of the unaffected individuals (n=127, 96 unrelated ethnically matched 
control samples and 31 unaffected KWE family members). We used the junction sequence 
which is only present in people with the tandem duplication to design an assay to detect the 
duplication. 
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C. 
 
Figure 3.1: Visualisation of the tandem duplication break points on the Integrative 
Genomics Viewer (IGV) 
(A) The sequence shows the junction sequence of the duplicated region, indicated by the 
change in case.  Capital bases indicate the sequence at the end of the duplicated region 
whereas the small bases indicate the sequence at the start of the duplicated region. The 
reads as viewed on IGV are shown in (B) and (C) where the grey bars show reads that align 
with the reference sequence (shown at the bottom of each image) and the coloured bases 
indicate the regions of mismatch from the reference sequence. The vertical broken lines in 
(B) and (C) indicate the start and end of the duplication. (C) The vertical broken line is at 
position chr8: 11 736 955 instead of where the base mismatch starts (chr8: 11 736 961) 
because according to Pindel this is where the breakpoint occurs. The start and end sites of 
the duplication have a “AGACA” sequence in common (red box at the bottom of B and C), 
and therefore these bases align perfectly with the reference sequence in C and therefore IGV 
does not show these bases as a mismatch, erroneously placing the duplication breakpoint at 
position 11 736 961 instead of 11 736 955. 
 
TGTTGGTCTATTATTTTGCCTCCTGTGTGCCAGGCACTGCAGCAGGCAGTGGGAACTGAATGTCAGCCCACCTGGAATGGA
ACTTGGGTCTAGGTTGGAGAagacagggtttcaccatgttggccaggctggtctcgaactcctgacctcgtgatccacctgcctcggccccccaaagtgc
tgggattacaggcgtgagcc 
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Figure 3.2: Mapping of the duplication breakpoints using gel electrophoresis and Sanger 
sequencing for the validation of the tandem duplication 
The junction sequence of the duplicated region is unique and is only present in individuals 
with the duplication. (A) An illustration of the duplication as it would appear on the 
chromosome. In the normal chromosome, region A is usually far from region B, which are 
the start and end of the duplication but these two regions are brought close to each other 
forming the junction sequence.  Primers were placed on either side of the junction which is 
unique to people with the duplication. (B) Gel electrophoresis of the PCR products using the 
primer pairs (in A) for the duplication junction region and a control amplicon from the LEP 
gene. The control amplicon (250 bp) is present in all samples and the duplication junction 
amplicon (375 bp) is present only in affected individuals (lanes 3, 4, 6 and 7). A=Affected, 
NA=not affected, NC=Negative blank control. (C) shows a fragment of the sequencing output 
of the 375 bp amplicon from B and clearly shows the junction sequence as indicated by the 
“AGACAG” sequence at the start of the junction sequence, indicated by the purple block.  
 
 
 
A A B 
7670bp 7670bp 
B 
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3.3. In silico functional analysis 
3.3.1.  Architecture of the tandem duplication 
The tandem duplication is located in an intergenic region 3627 bp upstream of the CTSB 
gene transcription start site as shown in Figure 3.3. Data from the ENCODE project 
annotated in the UCSC genome browser was investigated to determine whether the 
duplicated region included functional genomic elements. Based on DNAse I hypersensitivity 
site data, parts of the duplicated region lies in an open chromatin conformation in 
keratinocytes. Based on H3K4me1 histone modification data, a marker for regulatory 
elements, including inactive elements, the region overlaps with two regulatory elements. 
Based on H3K27ac data from NHEK, a marker for active enhancers, one of these regulatory 
elements is an enhancer element that is active in normal human epidermal keratinocytes 
(NHEK), the cell type affected in KWE. 
 
 
Figure 3.3: The tandem duplication lies upstream of the CTSB gene and overlaps with 
several regulatory elements 
The tandem duplication (highlighted in turquoise) lies upstream of the CTSB gene within the 
KWE critical region. The duplicated region overlaps with histone markers associated with 
regulatory elements. H3K4Me1 is associated with regulatory elements and the pink peaks in 
(A) show that the duplicated region overlaps with two regulatory elements.  
The duplication overlaps with the H3K27ac mark shown as the pink peak associated with 
active enhancers, suggesting that the region overlaps with an enhancer that is active in 
normal human epidermal keratinocytes (NHEK), the closest target cell type for KWE. Image 
generated using the UCSC genome browser (Kent et al., 2002). 
 
 
 
 
 
 
 
 
A 
B 
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3.3.2.  The tandem duplication overlaps with a tandem duplication in Norwegian KWE 
families 
During the course of the PhD study, we were contacted by Dr Torunn Fiskerstrand from 
Norway who was working with a dermatologist in Oslo who had identified patients with a 
phenotype compatible with a diagnosis of KWE.  Independently, they had identified a 15.93 
kb tandem duplication (chr8: 11 734 333-11 750 263) with a 95bp triplication in the middle 
of the duplication (chr8:11 744 352-11 744 446) in two Norwegian KWE families (Figure 3.4). 
This was done by whole genome SNP profiling, subsequent whole genome sequencing in two 
individuals and copy number variation analysis (Ngcungcu et al., 2017, Appendix H).  The 
South African and Norwegian tandem duplications overlap at a 2.622 kb region. This 2.62 kb 
overlapping duplicated region co-localizes with an active enhancer (detected by H3K27ac 
profiling) identified in NHEK cells (keratinocytes) (Figure 3.4). These data strongly suggest 
that the duplication of the enhancer within the 2.62 kb overlapping region is the causal 
genetic mutation for the KWE phenotype in both populations. 
 
 
Figure 3.4: The South African and Norwegian tandem duplications overlap at an enhancer 
region active in keratinocytes 
The South African (7.67 kb) and Norwegian (15.93 kb) tandem duplications are displayed as 
blue horizontal bars, located upstream of the CTSB gene. The 2.62 kb overlap (chr8: 11 734 
333-11 736 955) between the two duplications (turquoise shading) is clearly positioned at 
the site of an H3K27ac histone mark (pink peaks, enhancer activity) in the NHEK cell line. 
Image created using the UCSC genome browser (Kent et al., 2002). 
 
 
3.3.3. Transcription factor binding sites in the duplicated enhancer region 
Several transcription factors are predicted to bind to the duplicated enhancer region across 
various cell lines, and many are active in keratinocytes (Figure 3.5) (Kouwenhoven et al., 
2015; Wang et al., 2013). These include signal transducer and activator of transcription 3 
(STAT3) and CCAAT/Enhancer Binding Protein Beta (CEBPB) transcription factors, which are 
important for keratinocyte differentiation and function (Hauser et al., 1998; Zhu et al., 
1999).   
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Figure 3.5: Transcription factors that bind to the enhancer element common in the South African and Norwegian tandem duplications 
Schematic overview showing the 2.62 kb overlap with the active enhancer in the South African (7.67 kb) and Norwegian (15.93kb) tandem 
duplications (blue horizontal bars). The enhancer region includes binding sites for several transcription factors. The different transcription factors are 
displayed as bars with the strength of binding represented by the shade of colour from light grey to black with black indicating the strongest 
evidence for transcription factor binding. Transcription factor names are shown to the left of each bar. Image created using the UCSC genome 
browser (Kent et al., 2002). 
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3.3.4.  Frequency of the two duplications and other duplications/deletions in the KWE 
critical region  
No duplications of similar size or a duplication of the same size as the 2.62 kb overlap region 
have been reported in the Database of Genomic Variation (DGV). However, several non-
pathogenic duplications, deletions and inversions that encompass the duplicated regions 
(South African and Norwegian), and the CTSB and FTFD1 genes which are two of the closest 
genes to the duplicated regions (Figure 3.6), have been described in apparently healthy 
individuals. These larger duplication/deletion variants therefore do not appear to cause 
KWE.  
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Figure 3.6: CNVs in the KWE critical region reported in normal individuals overlapping with the duplicated region 
Schematic overview of the KWE critical region on chr8:11 525 326-11 987 757, with scale shown in the upper panel. Directly underneath, a large 
duplication identified in a Dutch cohort of 1416 healthy students (Bralten et al., 2011) and the South African (7.67 kb) and Norwegian (15.93kb) 
tandem duplications are displayed as blue horizontal blue bars. In the Database of Genomic Variants, no duplications (blue bars) of similar size to 
those described in South African and Norwegian patients (turquoise shade) have been reported. Several larger duplications (including the one in the 
Dutch cohort) are shown encompassing the region of the enhancer at chr8: 11 734 333-11 736 956 (large pink peak within the turquoise shade), but 
all of them include the CTSB gene and even the FDFT1 gene. Bar colour coding: Red=deletion, blue=duplication and brown=inversion. Image created 
using the UCSC genome browser (Kent et al., 2002). 
54 
 
3.3.5. Chromatin architecture in and around the duplicated regions 
3.3.5.1.  CTCF binding sites and interactions 
CCTC-binding factor (CTCF) binding often acts as insulators and restrict interactions between 
different regions of the genome (Bell et al., 1999). Therefore, conserved CTCF binding sites 
are important in gene regulation as they may act as a barrier between an enhancer and a 
gene. We assessed CTCF binding in the region around the enhancer in NHEK (keratinocyte) 
and in MCF-7 (breast cancer) cell lines. Figure 3.7 shows the CTCF binding in the two cell 
types. Notably, the CTCF binding in NHEK and MCF-7 is very similar, suggesting that the CTCF 
looping interactions would also be similar between the two cell types.  
 
 
CTCF interaction loops reveal parts of the genome that are in the same domain and are 
possibly interacting with each other and this binding also reveals regions that are cut off 
from other regions due to the binding of CTCF. ChIA-PET CTCF looping data are not available 
in NHEK, but since most of the CTCF binding positions that were examined between NHEK 
and MCF-7 are similar, we used interaction loops in MCF-7 to predict potential interaction 
loops in keratinocytes, thereby defining topological domains in the region. Data from the 
MCF-7 cell line pointed to larger domains that include the CTSB, FDFT1 and NEIL2 genes as 
well as the enhancer. Based on this domain structure, the enhancer would be able to 
associate with any of the regions overlapping with this domain including the promoters of 
CTSB, FDFT1 and NEIL2. A smaller subdomain within this region that contains only the CTSB 
gene and the enhancer was also observed. The smaller domain is particularly interesting 
since there are several lines of evidence for the presence of this smaller domain in 
replication studies using the MCF-7 cell line. This domain is much smaller and only includes 
the duplicated regions and the CTSB gene suggesting that under certain conditions, the 
enhancer only interacts with the CTSB gene and not with the other two genes in the larger 
domain. 
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Figure 3.7: Topological subdomains, CTCF binding sites and loops involving the enhancer and nearby genomic regions 
Schematic overview of the KWE critical region on chr8:11 560 000-11 880 000, with scale shown in the upper panel. The South African (7.67 kb) 
and Norwegian (15.93 kb) tandem duplications are displayed as blue horizontal bars, and the 2.67 kb overlap (chr8: 11 734 333-11 736 956) is 
marked across all horizontal panels (turquoise shading). (A) Shows that the CTCF binding sites are very similar in the NHEK (pink) and the breast 
cancer MCF-7 cell lines (black). (B) CTCF interaction data from ChIA-PET for the MCF-7 cell line showed that CTSB, FDFT1 and NEIL2 occur in the 
same topological domain with the enhancer, and a smaller subdomain exists, including only the CTSB gene and the enhancer.  
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3.3.5.2.  Topologically associating domains using Hi-C data 
Hi-C data reveal long and short-range chromosomal interactions which indicate DNA 
interactions. Low resolution NHEK Hi-C heat maps (Rao et al., 2014) show that the duplicated  
enhancer lies within a chromatin subdomain that includes the CTSB and FDFT1 genes (Figure  
3.8) suggesting that the region encompassing the enhancer may associate with the CTSB and 
FDFT1 genes in keratinocytes. This domain overlaps with the larger domain discussed in 
3.3.7.1 suggesting that under certain conditions, the enhancers interaction is limited to CTSB 
and FDFT1. 
 
 
Figure 3.8: NHEK Hi-C interactions around the duplicated region 
The heat map in the upper panel shows the topologically associating domains retrieved from 
HI-C data. The lower panel shows the region surrounding the duplicated region and the 
genes overlapping with the topological domain. The heat map shows that the duplications lie 
in the same topological domain (indicated by the blue lines) with CTSB and FDFT1.  The 
shading from white to deep red indicates the intensity which is based on the number of 
reads that suggest that the given regions interact. Only data with at least 40 reads is shown. 
Darker shades indicate that there is more evidence for the interactions (Figure drawn using 
3D Genome Browser at http://www.3dgenome.org). 
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3.3.6.  Chromatin interactions within the duplicated region 
To further examine possible intra-domain interactions within the region around the 
duplications, RNAPII ChIA-PET data from the MCF-7, K562, HeLa-S3, HCT116 and NB4 cell 
lines were analysed. Only MCF-7 and K562 interaction data are shown because enhancer 
interactions were only seen in these two cell lines. All enhancer interactions are shown in 
Table 3.1 and Figure 3.9.  Interactions between the enhancer and the CTSB promoter and 
gene body, but not with the promoters of FDFT1 or NEIL2 (Figure 3.9) were identified. In the 
K562 cells, the enhancer also appears to interact with the L-Threonine Dehydrogenase (TDH) 
pseudogene. Virtually all the observed RNAPII interactions in this region fall within the larger 
topological subdomain demarcated by strong CTCF binding in the MCF-7 cell line. The 
majority of the RNAPII-mediated chromatin interactions involving the CTSB promoter lie 
within the smaller subdomain that includes only the enhancer and the CTSB gene.  An 
interaction between the region of the duplicated enhancer and CTSB gene expression was 
noted in cancer cell lines using CHIA-PET data, thereby adding to the evidence that CTSB is a 
possible target gene for the duplicated enhancer. Additionally, there was no evidence that 
the enhancer interacts with FDFT1, NEIL2 and other genes in the region. 
 
Table 3.1: Interactions between the duplicated enhancer and nearby genes/regions based 
on CHIA-PET data 
Enhancer/gene interaction Target gene 
chr8:11724798..11726931-
chr8:11734409..11737375 
CTSB 
chr8:11727352..11730707-
chr8:11734493..11737265 
CTSB 
chr8:11200722..11203684-
chr8:11734586..11737466 
TDH, BC038546/LOC101929290 
chr8:11710084..11711593-
chr8:11733792..11735545 
CTSB 
chr8:11732515..11734330-
chr8:11735926..11737604 
Intergenic, between CTSB and the 
enhancer 
chr8:11717778..11719934-
chr8:11735920..11738113 
CTSB 
chr8:11724372..11727512-
chr8:11735176..11737878 
CTSB 
chr8:11724372..11727512-
chr8:11735176..11737878 
CTSB 
chr8:11724109..11726850-
chr8:11734821..11736918 
CTSB 
chr8:11734290..11736871-
chr8:11743194..11744743 
Intergenic, between CTSB and the 
enhancer 
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Figure 3.9: RNAPII ChIA-PET interactions between the enhancer and neighbouring CTSB 
K562 and MCF-7  RNAPII ChIA-PET interaction data show interactions between the enhancer and CTSB, but not with FDFT1 or NEIL2. The arrows 
indicate the interactions the between the enhancer and CTSB (not all shown). The purple arrow points to the enhancer’s interaction with the TDH 
gene.
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3.3.7.  Correlation of the duplicated enhancer activity with transcription of CTSB, FDFT1 
and NEIL2 
Based on the available data, the target and function of the duplicated enhancer, active in 
human keratinocytes, is unclear. Using histone markers to predict gene regulation through 
enhancer activity (H3K27ac) and transcription (H3K36me3), we examined the correlation of 
enhancer activity in the region with gene expression of three nearby genes, CTSB, FDFT1 and 
NEIL2. There was a strong correlation between the enhancer’s activity and CTSB across 
different cell lines including keratinocytes (P<<10-9 and R=0.74) (Figure 3.10). The correlation 
between FDFT1 transcription and duplicated enhancer activity is not correlated across 
different cell types (P<0.67 and R=-0.06). There was no evidence of NEIL2 transcription in 
keratinocytes and no strong correlation between the enhancer and NEIL2 transcription 
across different cell lines (P<-0.45 and R=-0.11).  
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Figure 3.10: Prediction of enhancer activity and transcription of nearby genes using 
ENCODE data 
The region of the South African (7.67 kb, green bar) and Norwegian (15.93kb, purple bar) 
tandem duplications is displayed, with the scale in the upper panel. The enhancer within the 
overlapping region was identified based on a DNase I hypersensitivity assay, shown here for 
keratinocytes (NHEK, blue peaks). Beneath this panel, the histone modification H3K27ac 
levels (ChIP-Seq data) across the enhancer region in 50 human tissue and cell types is shown 
as a regulation heat map (purple). Darker shades of purple indicate higher signal of the 
histone marker (H3K27ac), correlated to enhancer activity in the different tissues. 
Transcription of three nearby genes (CTSB, FDFT1 and NEIL2) was predicted by H3K36me3 
levels (ChIP-Seq data) across the genes in the same 50 different cell types. The transcription 
data are displayed as three parallel vertical bars in which red colour denotes high and green 
denotes low transcription activity. The correlations between H3K27ac and H3K36me3 levels 
are shown in the plots to the left. There was a highly significant positive correlation between 
the enhancer’s activity and CTSB expression (p<10-8).  
 
 
 
 
61 
 
3.4.  In vitro functional analysis in skin biopsies 
The functional analysis was done in both the South African and Norwegian KWE cases (n=7 in 
each group) and controls (n=7 in each group)  in collaboration with Drs Friskerstand and 
Sitek and their groups from Norway and Prof Joost Schalkwijk from The Netherlands. 
Samples were collected from the palmar skin of affected and control individuals. In the 
affected individuals, the biopsy was taken from non-lesioned skin that did not appear to be 
peeling at the time of sampling (Figure 2.5). Each biopsy was cut in half and one half was 
used for the relative gene expression studies and the remaining half was used for histology 
and immunohistochemistry. 
 
 
3.4.1.  Relative gene expression for CTSB, FDFT1 and NEIL2 
We compared the relative gene expression levels of CTSB, FDFT1 and NEIL2 in palmar 
epidermis of affected individuals (n=6 [2 South Africans and 4 Norwegians]) to unaffected 
individuals (n=7 [3 South Africans and 4 Norwegians]), using qRT-PCR (Table 3.2). One 
affected South African sample was excluded from further analysis due to low RNA quality 
and quantity. Each cDNA sample was run in triplicate and the average CT values, expression 
ratio’s (ΔCt) and fold change were calculated for each sample (Table 3.2). The test genes 
(CTSB, FDFT1 and NEIL2) were normalised to one housekeeping gene, RPLP0. RPLP0 is an 
appropriate exogenous control for keratinocytes (Minner and Poumay, 2009). Because of the 
small sample size in the individual Norwegian and South African groups, the data were 
analysed together.  The relative expression level of CTSB was significantly higher in the skin 
from the affected individuals compared to controls (p=0.001) (Figure 3.11). There was no 
statistically significant difference in the expression of FDFT1 (p=0.29) or NEIL2 (p=0.44) 
between the two groups. Although there was no significant difference in the expression of 
FDFT1 and NEIL2 in the combined group, visually, the expression of the two genes appears to 
be slightly higher in the South African affected samples compared to the controls. Due to the 
small sample size, we were unable to determine if these differences were statistically 
different in the South African group. 
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 Table 3.2: Average CT values and fold changes for CTSB, FDFT1 and NEIL2 
Sample Status* Sex Test_gene_CT** RPLP0_CT** Fold 
change 
Average 
fold 
change 
Standard 
errors of 
the mean 
CTSB** 
NOR _Ctr1 N F 26.21 21.86 1.39 
1.16 0.19 
NOR _Ctr2 N F 26.02 21.72 1.45 
NOR _Ctr3 N F 25.73 21.72 1.78 
NOR _Ctr4 N F 25.75 21.78 1.81 
SA_Ctr1 N F 28.7 22.48 0.38 
SA _Ctr2 N F 27.45 22.24 0.77 
SA _Ctr3 N M 27.96 22.19 0.52 
OSL_DII-1 A F 24.55 22.62 7.46 
5.95 0.93 
OSL_DII-6 A F 24.65 22.77 7.77 
OSL_DIII-6 A F 24.22 22.05 6.29 
OSL_EI-2 A F 23.83 22.12 8.67 
SA_KWE2 A M 24.57 21.55 3.49 
SA_KWE3 A M 26.19 22.37 2.02 
FDFT1** 
NOR _Ctr1 N F 29.4 21.86 1.33 
1.21 0.22 
NOR _Ctr2 N F 28.74 21.72 1.9 
NOR _Ctr3 N F 28.81 21.72 1.82 
NOR _Ctr4 N F 28.74 21.78 1.98 
SA_Ctr1 N F 31.45 22.48 0.49 
SA _Ctr2 N F 31.24 22.24 0.48 
SA _Ctr3 N M 31.25 22.19 0.46 
OSL_DII-1 A F 29.55 22.62 2.02 
1.62 0.13 
OSL_DII-6 A F 30.09 22.77 1.54 
OSL_DIII-6 A F 29.19 22.05 1.74 
OSL_EI-2 A F 29.05 22.12 2.01 
SA_KWE2 A M 28.98 21.55 1.43 
SA_KWE3 A M 30.33 22.37 0.99 
NEIL2** 
NOR _Ctr1 N F 29.91 21.86 2.17 
1.41 0.3 
NOR _Ctr2 N F 29.75 21.72 2.21 
NOR _Ctr3 N F 29.24 21.72 3.15 
NOR _Ctr4 N F 30.7 21.78 1.19 
SA_Ctr1 N F 32.85 22.48 0.44 
SA _Ctr2 N F 32.54 22.24 0.46 
SA _Ctr3 N M 33.2 22.19 0.28 
OSL_DII-1 A F 30.86 22.62 1.9 
1.96 0.22 
OSL_DII-6 A F 30.97 22.77 1.95 
OSL_DIII-6 A F 30.33 22.05 1.85 
OSL_EI-2 A F 29.64 22.12 3.11 
SA_KWE2 A M 29.55 21.55 2.24 
SA_KWE3 A M 32.01 22.37 0.73 
* N=Not affected, A=Affected; ** CT= Cycle threshold for each of the test genes or the endogenous control  
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Figure 3.11: Relative expression of three nearby genes that occur in the same domain with 
the duplicated enhancer 
Relative expression was calculated using the ΔCt method. Solid circles represent KWE 
patients and hollow circles the controls. In the combined South African and Norwegian 
sample, the expression of CTSB is significantly higher in affected individuals compared to 
controls (p=0.001), whereas there was no significant difference in the expression of FDFT1 
(p=0.29) and NEIL2 (p=0.44) in affected compared to unaffected individuals. 
 
 
3.4.2. Immunohistochemistry 
3.4.2.1.  Histology  
Haemotoxylin and Eosin (H&E) staining of the patient samples showed a thicker epidermis 
and stratum corneum compared to control palmar skin and the morphology was largely 
normal, with all epidermal layers present and an orthokeratotic stratum corneum (Figure 
3.12). As the biopsies were taken from non-lesioned skin, there was no overt blistering or 
stratum corneum splitting visible, nor was parakeratosis evident (Findlay and Morrison, 
CTSB 
 p=0.001 
NEIL2 FDFT1 
p=0.29 
IL  
 p=0.44 
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1978). Morphology was otherwise unremarkable with no evidence of the changes seem in 
the active phase which is characterized by basaloid hyperplasia, spongiosis, and horny layer 
showing parakeratosis and a split.  However, the epidermis from the affected skin was much 
thicker than the epidermis from control skin. Additionally, the number of granular layers was 
increased in affected skin compared to the skin of controls (Table 3.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Haemotoxylin and Eosin (H&E) staining of hand palm biopsies of a healthy 
control (normal skin) and KWE patient (affected skin) 
The epidermis in the affected individuals was notably thicker in affected skin compared to 
normal skin. SC: stratum corneum, SL: stratum lucidum, SG: stratum granulosum, SS: stratum 
spinosum, SB: stratum basale, D: dermis. The scale bar is 50µm. 
  
 
3.4.2.2.  Immunohistochemistry 
As a part of a collaboration with our Dutch colleagues, the protein abundance and 
localisation of CTSB, FDFT1 and NEIL2 were determined in the biopsies from affected (3 
South African and 4 Norwegian) and control (3 South African and 4 Norwegian) individuals. 
CTSB was found to be present in the stratum spinosum of control and affected skin in a 
granular pattern throughout the epidermis, consistent with a lysosomal localization. 
However, the amount of CTSB in the stratum granulosum was either absent or weak in 
controls but always present in the stratum granulosum of affected skin, varying from weak 
(3 out of 7)to strong (4 out of 7)  (Figure 3.13, Table 3.3). Semi-quantitative scores (Table 3.3) 
for CTSB stratum granulosum staining were significantly higher in affected skin (1.7 ±1.0 
(mean±SD)) compared to controls (0.3±0.5 (mean±SD)) (p=0.006). FDFT1 stained very feint 
staining and no staining was observed for NEIL2 in both affected individuals and controls.  
 
SL 
SC 
SS 
SB 
SG 
D 
Control KWE 
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Figure 3.13: CTSB staining in a control individual and KWE case 
CTSB is present in a granular pattern in the stratum spinosum of  control and KWE skin. Note 
that CTSB staining is absent in the stratum granulosum of control skin, whereas it is strongly 
expressed in the stratum granulosum of KWE skin. SC: stratum corneum, SG: stratum 
granulosum, SS: stratum spinosum, SB: stratum basale. Note the increased epidermal 
thickness of the KWE skin. SC: stratum corneum, SG: stratum granulosum, SS: stratum 
spinosum, SB: stratum basale. Note the increased epidermal thickness of the KWE skin. 
Magnification= 20X. The scale bar is 50µm. 
 
 
Table 3.3: Number of granular layers and CTSB staining intensity in affected and control 
skin 
Sample # of granular layers CTSB staining intensity 
NOR _Ctr1 2 0 
NOR _Ctr2 3 0 
NOR _Ctr3  3-4 1 
NOR _Ctr4 4 1 
SA_Ctr1 4 0 
SA _Ctr2 4 0 
SA _Ctr3 3 0 
NOR_DII-1 6 2.5 
NOR_DII-6  4-5 2.5 
NOR_DIII-6 4 1 
NOR_EI-2 6 0.5 
SA_KWE2 5 2.5 
SA_KWE3 5 2.5 
SA_KWE1 4 0.5 
                        *Intensity of CTSB staining in the granular layer of the epidermis 
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3.5.  Summary of the results  
NGS data revealed that there were no small variants or structural variants overlapping with 
the coding regions that segregated exclusively with KWE across all families. However, a large 
intergenic 7.69 kb tandem duplication overlapping with an enhancer known to be active in 
keratinocytes segregated with all affected individuals in all the South African KWE families 
studied. This tandem duplication overlaps with a 15.93 kb Norwegian tandem duplication at 
the enhancer element across a 2.62 kb region. This enhancer appears to regulate CTSB gene 
expression in normal keratinocytes and other cells. In the presence of the duplicated 
enhancer, CTSB expression was significantly upregulated in the palmar skin of individuals 
with KWE and there was an overabundance of CTSB in the granular layer of affected 
individuals. We therefore showed that the duplication of the enhancer leads to CTSB 
overexpression and CTSB overabundance in affected individuals. 
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Chapter 4 
 
Discussion 
 
The genetic cause of KWE, an autosomal dominant disorder, eluded researchers for decades. 
KWE was first described four decades ago (Findlay et al., 1977). In 1985, Peter Hull, a PhD 
candidate at the time, did a genealogical study on South African KWE families using their 
family histories including, birth, death and baptism records and found that the KWE families, 
including the Coloured families, could be traced back a single founder,  Captain Francois 
Renier Duminy, a French mariner who settled in South Africa in the late 1700s (Hull, 1986). 
Hull, and Findlay et al. (1977) before him, suggested that KWE was common in South Africa 
due to genetic drift by founder effect, thereby suggesting the genetic mutation in South 
African families would be the same mutation across all these families. Subsequently, the 
keratin genes were excluded as candidates of KWE in South African patients (Spurdle and 
Starfield, unpublished data cited by Starfield et al., 1997).  Two decades ago, the causal 
mutation was localized to 8p23.1-22 (KWE critical region) using linkage analysis (Starfield et 
al., 1997). The data showed that affected individuals share a common haplotype, confirming 
that the cause was due to a single founder mutation in South African families (Starfield et al., 
1997). Since then, a number of studies have interrogated the coding regions in the KWE 
critical region and excluded coding mutations in several genes including the FDFT1 and CTSB 
(Appel et al., 2002; Hobbs et al., 2012).  
 
 
The aim of this study was to identify and characterize the causal mutation for KWE in South 
African families. Targeted resequencing of 8p23.1-22 was performed in three KWE families 
and seven unrelated, ethnically matched controls. No plausible novel, coding or regulatory 
small variants (SNVs or small indels) that segregated exclusively with the disease were 
identified. However, a tandem duplication that segregates completely with KWE and 
overlaps with an enhancer element active in keratinocytes was identified in all affected 
South African individuals. This tandem duplication overlaps with a tandem duplication 
identified in affected Norwegians and there is an enhancer element in the region of overlap.  
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4.1. Exclusion of small variants as causal variants for KWE 
In this study, we performed target capture resequencing of 8p23.1-22 and found no 
plausible KWE causative small variants (SNVs or small indels) that were novel and coding or 
in regulatory regions, and that segregated exclusively with the disease.  However, a novel 
intronic variant within the FDFT1 gene was identified in all sequenced affected individuals 
but was excluded as a possible plausible causal variant because it did not overlap with any 
regulatory elements and there was insufficient evidence to suggest that the variant was 
causal.   
 
 
4.2.  Identification of a novel non-coding tandem duplication as the causal variant for 
KWE 
We identified a novel 7.67 kb tandem duplication in a non-coding region within the KWE 
critical region, upstream of the CTSB gene that segregated completely with the disease in 
seven KWE families.  The duplication overlaps with a novel, independently identified tandem 
duplication in two Norwegian families with the KWE phenotype. The South African and 
Norwegian duplications have a 2.62 kb region in common that encompasses an active 
enhancer element (based on H3H27Ac histone ChIP-seq data) that has been shown to be 
active in normal human epidermal keratinocyte cell lines (NHEK) (Figure 3.3 and 3.4), 
differentiating keratinocytes (Figure 4.1) (Ngcungcu et al., 2017) and several other cell lines 
used in the ENCODE and Epigenome Roadmap projects (Figure 3.10).  Both the South African 
and Norwegian duplications are novel as no duplications with the same break points have 
been reported (Figure 3.6). Interestingly, larger duplications that include both duplications 
and CTSB only or CTSB and FDFT1, have been reported in apparently healthy individuals and 
have no obvious health implications, suggesting that it is the duplication of the smaller 
target region that is implicated in the disorder (Smith et al., 2004).  
 
 
Several transcription factors were shown to bind to the enhancer across various cell lines 
(Figure 3.5) (Kouwenhoven et al., 2015; Wang et al., 2013) and are active in keratinocytes 
(Ngcungcu et al., 2017). The signal transducer and activator of transcription 3 (STAT3) and 
CCAAT/Enhancer Binding Protein Beta (C/EBPB) proteins along with p63 are important in 
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keratinocyte differentiation and function and mutations or altered regulation of these genes 
are known to alter keratinocyte differentiation  (Hauser et al., 1998; Smith et al., 2004; Zhu 
et al., 1999). 
 
 
 
 
 
 
 
 
 
Figure 4.1: ChIP-Seq analyses of H3K27ac during human primary keratinocytes (HKC) 
differentiation. 
Schematic overview of the KWE critical region on chr8:11 560 500-11 905 700, with the scale 
shown in the upper panel. The South African (7.67 kb) and Norwegian (15.93 kb) tandem 
duplications are displayed as blue horizontal bars. The H3K27ac histone modification signal 
(pink peaks) represents enhancer activity. The region corresponding with the 2.62 kb overlap 
between the duplications is indicated by the block over the H3K27ac peaks. Each line in the 
pink panel indicates different days of keratinocyte differentiation. From the first pink line: 
Day 0, day 2, day 4 and the last line is day 7 of keratinocyte differentiation. The enhancer is 
active throughout the first seven days of keratinocyte differentiation. 
 
 
4.2.1.  Copy number variation of non-coding regions as an unusual mechanism for disease 
causation 
Because the enhancer is duplicated in the South Africa and in the Norwegian patients and is 
active in the cell type closest (non-palmoplantar epidermal keratinocytes) to the cell types 
affected in KWE patients (palmoplantar epidermal keratinocytes), we proposed that the 
duplication of the enhancer is the genetic cause for KWE. Copy number variation (CNV) 
including large insertions, deletions, duplications and inversions occurs across the genome 
and can either be benign or result in phenotype variation or cause disease. In cases where 
CNVs result in a diseased state, the coding regions are usually involved. Duplications of 
genes or portions of genes have been implicated in a several of Mendelian disorders  but the 
duplication of non-coding regulatory region is a far less common disease mechanism 
although they have been previously reported, primarily in limb malformation disorders 
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(Dathe et al., 2009; Klopocki et al., 2011; Lohan et al., 2014). Amongst these are duplications 
that overlap with an enhancer known as the Zone Polarizing activity (ZPA) regulatory 
sequence (ZRS) which regulates expression of the sonic hedgehog (SHH) gene (Lohan et al., 
2014) . Through ZRS regulation, SSH is expressed in the posterior region of the limb bud 
(ZPA) and determines the anterior-posterior axis in the limb bud during development. 
Several studies have shown that microduplications that overlap with the ZRS result in several 
polydactylies and syndactylies (Dathe et al., 2009; Lohan et al., 2014). Lohan and colleagues 
(2014) showed that overlapping microduplications caused Hass-type polysyndactyly (HTS) 
(larger duplication) and Laurin-Sandrow syndrome (LSS). HTS and LSS have overlapping 
phenotypes but LSS is more severe, with the smaller duplications causing the more severe 
phenotype (Lohan et al., 2014). Dathe and colleagues (2009) identified a 5.5 kb tandem 
duplication downstream of BMP2 that was associated with an autosomal-dominant trait, 
brachydactyly type A2 (BDA2). BDA2 is a limb malformation characterized by hypoplastic 
middle phalanges of the second and fifth fingers. The duplication contains highly conserved 
sequences that are proposed to function as a cis-regulatory element regulating BMP2 
expression in the limb.  
 
 
4.3. Functional impact of the enhancer element 
4.3.1.  The enhancer occurs in the same topological domain as CTSB, FDFT1 and NEIL2 
Using publically available data, we interrogated the genomic region around the enhancer in 
an effort to determine the target gene for the enhancer in the absence of the duplicated 
enhancer. Hi-C data showed that the enhancer occurs in the same topologically associating 
domain as CTSB and FDFT1 (Figure 3.8). These data are low resolution and fine mapping of 
interesting regions is often required. Using CTCF binding sites in the NKEK and MCF-7 cell 
lines and CTCF interaction loops in MCF-7 cell lines, we showed that the enhancer lies in the 
same large topological domain with CTSB, FDFT1 and NEIL2 (Figure 3.7). These data also 
showed that a smaller subdomain within the larger domain exists and only includes the 
enhancer and the CTSB gene suggesting that in some instances, the enhancer may only be 
able to interact with CTSB but not the other two genes in the larger domain. NHEK CTCF 
binding data was available but CTCF interaction data were never generated. Oti and 
colleagues (2016), designed a tool that is able to predict CTCF interactions using CTCF 
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binding site  data (Oti et al., 2016) and this tool predicted similar loops to those 
experimentally determined in MCF-7 cells (Figure 4.2)  (Ngcungcu et al., 2017).  These data 
showed that 1) the enhancer and CTSB and 2) the enhancer and CTSB, FDFT1 and NEIL2 were 
in the same domain and therefore, under certain conditions, the enhancer could in theory 
be able to interact with either of the three genes or exclusively with CTSB. 
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Figure 4.2: CTCF binding sites, MCF-7 interaction loops and NHEK predicted CTCF interaction loops. 
Schematic overview of the KWE critical region on chr8:11 560 000-11 880 000, with the scale shown in the upper panel. The South African (7.67 
kb) and Norwegian (15.93 kb) tandem duplications are displayed as blue horizontal bars, and the 2.62 kb overlap (chr8:11 734 333-11 736 955) 
is marked across all horizontal panels (turquoise shading). (A) CTCF binding sites in the keratinocyte (NHEK, pink peaks) and the breast cancer 
(MCF-7, black peaks) cell lines are highly similar. (B) ChIA-PET CTCF data from MCF-7 cells showing that CTSB, FDFT1 and NEIL2 may occur in the 
same topological domain with the enhancer (Rep 1 (Repetition 1)). A smaller subdomain exists that only includes the CTSB gene and the 
enhancer (Rep 1 and 2). (C) Using the CTCF binding sites identified in NHEK cells, CTCF interaction loops (and hence subdomains) in these cells 
were predicted (Oti et al., 2016). These data indicate a larger subdomain extending from the strong CTCF binding site close to the DEFB136 
gene to the GATA4 gene, and a smaller subdomain, including only the enhancer and CTSB.  
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4.3.2.  The enhancer interacts with the promoter of CTSB 
We examined RNA polymerase II (RNAPII) binding which is required for transcription and 
interacts with the promoter, and indirectly with the enhancer. RNAPII interactions were 
determined using ChIA-PET data which identify regions of the genome that interact with 
each other through RNAPII binding. It is expected that using this data, based on the 
interaction of the enhancer to a particular gene, we could determine the target gene for the 
enhancer. Because these experiments had only been performed in the cancer cell lines, data 
from five cancer cell lines were analysed. The enhancer only showed interactions in the 
leukemia (K562) and the breast cancer (MCF-7) cell lines.  Using these data, it was clear that 
the enhancer interacts with the CTSB gene but not with the other two genes in the same 
domain as the enhancer, this was observed in 2 replicates in both cell lines. In one replicate 
of the K562 cell line, one other interaction was noted with the L-Threonine Dehydrogenase 
(TDH) gene, which is a pseudogene (Table 3.1 and figure 3.9) (Edgar, 2002). Only one line of 
evidence suggested that the enhancer interacts with the TDH gene and because this is a 
pseudogene, it is unlikely that its altered enhancer interaction could lead to a disease.  
 
 
4.3.3.  The enhancer’s activity correlates with the expression of CTSB in keratinocytes and 
other cells 
Using H3K27ac and RNAPII ChIP-seq data, our collaborators analysed enhancer activity 
(H3K27ac) and gene expression (RNAPII) for CTSB, FDFT1 and NEIL2 in differentiating 
epidermal keratinocytes over seven days (Figure 4.3) (Kouwenhoven et al., 2015; Ngcungcu 
et al., 2017). The enhancer’s activity was highly correlated, but not with statistical 
significance, with CTSB expression during differentiation of normal keratinocytes but not 
with FDFT1 and NEIL2 expression. Additionally, we analysed ENCODE and Epigenome 
Roadmap data from 47 cell lines and observed a strong correlation between the enhancers 
activity and CTSB transcription (H3K36me3 histone mark) across the cell lines, including 
NHEK (Figure 3.10).  
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Figure 4.3: Activity of the enhancer and the three nearby genes during keratinocyte 
differentiation. 
The enhancer’s activity and gene expression were determined from H3K27Ac and RNAPII 
ChIP-seq data, respectively. There was a strong correlation between the enhancer’s activity 
(black line) and the expression of CTSB (red broken line) although it was not statistically 
significant (R=0.93, p=0.07). There was no significant correlation between the enhancer 
activity and FDFT1 (green broken line; R=0.003, p=1) and NEIL2 (blue broken line: R=-0.37, 
p=0.63)  (Ngcungcu et al., 2017). 
 
 
Taken together, the presence of CTSB in the same domain as the enhancer along with the 
RNAPII interaction data and the correlation of the enhancer’s activity with CTSB expression 
in keratinocytes and other cell types, suggest that the enhancer regulates the expression of 
CTSB. It was therefore important to perform in vitro studies in KWE affected skin to 
determine how the enhancer affects the expression of its target gene, CTSB, and/or the 
other genes in the same domain as the enhancer. 
 
 
4.4.  The duplication of the enhancer leads to the overexpression of its target gene, 
CTSB 
Different lines of evidence suggest that the normal enhancer regulates CTSB but it is still 
unclear which gene or genes are dysregulated in the presence of the duplication. The 
enhancer may dysregulate the expression of its target gene or the expression of a different 
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gene through enhancer adoption, probably of one of the genes in the same domain with the 
enhancer. We collected palmar skin biopsies from affected and control individuals and 
performed qPCR, histology and immunohistochemistry to determine the expression levels of 
the three genes in the same topological domain as the enhancer and the site and level of 
expression of their products. In KWE cases, the biopsy was taken from non-lesioned skin. 
 
 
We analyzed the South African and Norwegian data together because the South African 
sample size was too small. In the combined South African and Norwegian group, the 
expression of CTSB was significantly higher in affected individuals compared to controls 
(Figure 3.11).  The expression levels for CTSB are much higher in the Norwegian group 
compared to the South African group. It is unclear why this difference exists. It may be a 
confounding factor due to the fact that the RNA for the South African and Norwegian 
samples were extracted at different times and the RNA concentrations (for the test genes 
and the reference gene) in the South African samples were lower compared to the 
Norwegian samples. The differences in expression levels in the two groups may also be 
biological, as the South African and Norwegian duplications are different in size and position 
of the breakpoints. Lohan and colleagues (2014) showed that overlapping tandem 
duplications of different sizes caused similar phenotypes but the severity of the phenotype 
varied based on the size of the duplication. The smaller duplication caused LSS which is a 
more severe phenotype compared to HSS which is caused by a larger tandem duplication 
(Lohan et al., 2014). The different sizes of the duplications may cause different chromatin 
conformational changes in response to environmental stimuli and may therefore affect gene 
expression in a different way. The KWE phenotype appears to be more severe in South 
Africans compared to Norwegians (Hull, 2015, personal communication). CTSB abundance 
was significantly higher in the granular layer of affected individuals compared to controls 
(Table 3.3, Figure 3.13) whereas FDFT1 stained very faintly and no staining was observed for 
NEIL2. CTSB was present in the spinous layer of the epidermis in both affected and control 
skin. 
 
Interestingly, in a previous South African  study that examined gene expression of CTSB and 
FDFT1 in wedge biopsies (without separation of the epidermis from the dermis), Hobbs and 
 
 
76 
 
colleagues (2012) did not observe an increase in the expression of CTSB in affected skin 
(Hobbs et al., 2012). Although the finding of the previous study did not observe an increase 
in CTSB in affected individuals, the evidence presented in the current study clearly show that 
CTSB expression is significantly increased in affected individuals and this increased 
expression is the likely altered pathway that leads to KWE. The authors concluded that the 
elevated expression of FDFT1 that they observed in their study was likely due to a response 
to an intracellular cholesterol deficit caused by the  inflammation associated with KWE 
during a peeling cycle (Hobbs et al., 2012). This elevation was not observed in the current 
study possibly due to the differences in the cycle of the skin peeling where the biopsies were 
collected (lesioned skin, in the Hobbs study vs non-lesioned skin in the current study). 
 
 
4.5. Overexpression of CTSB and ectopic localisation of CTSB as a plausible cause for the 
KWE phenotype 
The CTSB gene encodes cysteine cathepsin B (CTSB) which is a lysosomal protease of the 
papain enzyme family (Li et al., 2016; Turk et al., 2012). CTSB is one of eleven known human 
cathepsin subtypes (Li et al., 2016) and has homologues in other mammals. CTSB shows 
endopeptidase and carboxydipeptidase activity and is localised in lysosmal compartments of 
different tissue including the epidermis (Nagler et al., 1997; Rowan et al., 1993; Tholen et al., 
2013). CTSB and many other cathepsins are ubiquitously expressed and are involved in 
protein degradation and turnover (Tholen et al., 2013; Turk et al., 2012). CTSB is associated 
with several cancers and other disorders including pancreatitis (Aggarwal and Sloane, 2014; 
Mahurkar et al., 2006; Yang et al., 2016). CTSB and its product are biologically plausible 
candidates for KWE because of its role, and that of other cathepsins and cathepsin 
inhibitors, in keratinocyte differentiation and disorders of keratinization.  
 
 
4.5.1. CTSB affects keratinocyte cell-cell dissociation and keratinocyte migration  
CTSB is abundant throughout the epidermal layers and secreted into pericellular spaces by 
keratinocytes (Büth et al., 2004). CTSB is contained within lysosomes in the cytosol of basal 
and spinous cells. Within the spinous layer, CTSB containing lysosomes can also be found 
close to desmosomes of the spinous layer keratinocytes and CTSB is therefore thought to be 
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secreted into the extracellular matrix between the keratinocytes in this layer (Büth et al., 
2004). This is achieved through the migration of CTSB containing lysosomes from the region 
near the nucleus to the cell periphery then into the extracellular region during keratinocyte 
migration (Büth et al., 2004). It was also shown that CTSB was proteolytically active on the 
cell surfaces of migrating keratinocytes and that it  has a role in cell-cell dissociation and 
degradation of the extracellular matrix allowing for cell migration during wound healing 
(Büth et al., 2007; Büth et al., 2004). When CTSB was inhibited in wounded cells, 
keratinocyte migration was impaired thereby suggesting that CTSB has a role in keratinocyte 
migration (Büth et al., 2007; Büth et al., 2004). In the case of KWE affected skin, CTSB was 
highly abundant in the granular layer rather than the spinous layer. Overexpression of CTSB 
in the granular layer may be causing accelerated keratinocyte dissociation and migration, 
thereby affecting the formation of the stratum corneum. 
 
 
4.5.2. Absence of cathepsin inhibitors cause skin peeling disorders 
Keratinocyte cornification and desquamation is controlled by a fine tuned balance between 
different proteases (including several cathepsins), and their inhibitors (Brocklehurst and 
Philpott, 2013; Zeeuwen, 2004). Interestingly, loss of function mutations in the gene 
encoding cystatin A (CSTA), an important inhibitor of CTSB and other cathepsins (Figure 4.4) 
cause phenotypes that have overlapping characteristics with KWE. CSTA is a thiol proteinase 
inhibitor and is a member of the stefins family of cystatins (cystatin family I) (Pavlova et al., 
2000). CTSA has been shown to interact with several cathepsins including CTSB, and 
different isoforms of CTSL (Figure 4.4). CSTA inhibits CTSB through a two-step mechanism 
that involves an initial weak CTSB-CSTA link followed by a second tighter link that results in 
the conformational change of CTSB through the removal of the essential occluding loop in 
CTSB (Pavlova et al., 2000). Although CSTC (CST3 in Figure 4.4)  inhibits CTSB in the same 
manner as CSTA but does so more efficiently (Pavlova et al., 2000), we only focused on the 
CSTA because the absence of this inhibitor leads to phenotypes that have overlapping 
characteristics with KWE.   
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Figure 4.4: StringDB output showing interactions of CSTA and CTSB with other proteins. 
The pink line indicates that the interactions between the query protein (CSTA in A and CTSB 
in B) and other proteins were determined experimentally. Only high confidence interactions 
scores (0.7) are shown (Szklarczyk et al., 2015). 
 
 
CTSA has an important role in desmosome-mediated cell-cell adhesion in the lower levels of 
the epidermis (Blaydon et al., 2011). In the epidermis, CSTA is expressed in stratum 
spinosum, stratum granulosum and the stratum corneum (Blaydon et al., 2011; 
Palungwachira et al., 2002) and secreted in normal sweat (Kato et al., 2005).  Homozygous 
mutations in the CSTA gene lead to the absence of the protein causing exfoliative ichthyosis  
(PSS4) (Blaydon et al., 2011). Like KWE, affected individuals present as early as infancy, the 
palms and soles are affected and symptoms worsen when affected arrears are exposed to 
moisture. The disorder however, is non-erythematous and like the Norwegian KWE cases, 
the condition does not appear to be affected by seasonal change. Interestingly, the strongest 
synthesis of CSTA in normal skin occurs in the granular layer (Blaydon et al., 2011), this is the 
same layer where CTSB shows the strongest signal in KWE skin (Figure 3.13). This layer is 
subjected to apoptosis and temporary degradation during a KWE exacerbation (Hull et al., 
2013), which could be explained by secretion of cathepsin B rising above a threshold 
triggering the lysosomal apoptosis pathway (de Castro et al., 2016). With the abundance of 
CSTA in the granular layer, one would expect that CTSB is significantly inhibited in this layer 
as seen in the normal skin of our control samples where CTSB was present at much lower 
levels in this layer compared to the controls. This suggests that CTSA is essential to maintain 
A.  B.  
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low CTSB abundance in this layer for normal differentiation to occur. In the presence of the 
enhancer duplication, the abundance of CTSB is drastically increased and there likely is not 
enough CSTA in this layer to sufficiently inhibit CTSB leading to the inappropriate proteolysis 
of proteins required to successfully complete terminal keratinocyte differentiation. 
Homozygous mutations in CSTA also cause acral peeling skin syndrome (APSS), which like 
exfoliative ichthyosis is exacerbated by moisture and has  skin desquamation phenotypes 
very similar to KWE (Krunic et al., 2013). Additionally, the deficiency of cystatin M/E, another 
cysteine protease inhibitor that also targets CTSB, causes an ichthyosis phenotype in mice 
(Zeeuwen et al., 2002).  
 
 
These data suggest that the tight regulation of the expression pattern and level of CTSB and 
its inhibitors is crucial for regulating terminal keratinocyte differentiation. Moisture was a 
common trigger in the two human examples described above. Moisture is also a major 
factor in the presentation of KWE along with triggers that are more common in factors that 
occur in the winter (possibly cold conditions) which may play an important role in the 
pathways involved in protein regulation in the epidermis. In the case of KWE, chromatin 
conformation is important and this is likely altered in the presence of the duplication under 
environmental stressors.  It may need a particular conformation that would lead to both 
enhancers having access to CTSB and may impact the CTSB promoter leading to the 
overexpression of CTSB.  
 
 
4.5.3.  Other cathepsin genes and their role in skin disease  
Loss of function mutations in other cathepsin genes have also been shown to cause skin 
phenotypes both in humans and animals (Büth et al., 2004; Egberts et al., 2004; Horikoshi et 
al., 1998; Nishimura et al., 2002; Reinheckel et al., 2005; Roth et al., 2000; Schwarz et al., 
2002; Toomes et al., 1999) with a pertinent example being the Papillon Lefèvre syndrome 
characterized by palmoplantar hyperkeratosis, periodontal disease and mutations in 
cathepsin C (Toomes et al., 1999). CTSL has been shown to regulate epidermal homeostasis 
as recessive mutations in CTSL have been shown to cause murine keratinocyte and hair 
follicle epithelial cell hyper proliferation (Roth et al., 2000). Notably, altered expression of 
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cathepsins can alter the localization of epidermal differentiation-related proteins. Murine 
CTSD, which plays a role in intracellular and extracellular catabolism, was shown to regulate 
transglutaminase 1, an important cornified envelope crosslinking protein (Egberts et al., 
2004).  In the absence of CTSD, the activity of transglutaminase 1 was significantly reduced 
and the concentration of other crucial differentiation and cornified envelope proteins such 
as keratins K1 and K5, loricrin, involucrin and filaggrin were altered (Egberts et al., 2004). The 
absence of CTSD also disrupted the structure of the epidermis, particularly the stratum 
corneum (Egberts et al., 2004). Similar to other cathepsins, altered expression and 
localization of CTSB may in turn alter expression of other genes and localization of proteins 
important in keratinocyte differentiation and maintenance of epidermal homeostasis leading 
to the KWE phenotype.    
 
 
4.6.  Study Limitations 
There were a few minor limitations in the study and these are based on the limitations that 
we had in terms of the functional studies that we were able to do. The first limitation was 
that we had a small sample size for the functional studies. This was mainly due to the 
invasiveness of collecting the skin biopsy samples needed for the study. It was therefore 
difficult to recruit a large number of people for this experiment. As a result we had a small 
sample size for the gene expression analysis and immunohistochemistry. Although it is clear 
that CTSB is involved in KWE pathogenesis, it is still unclear whether FDFT1 has a biological 
role in affected South African individuals. A larger sample size would help resolve this 
matter. 
 
 
The second limitation was that we only examined the gene expression and protein 
abundance patterns of the three genes in the same topological domain as the enhancer. If 
there were additional interactions with the enhancer originating from beyond the 
topological domain, our assays would not detect these changes.  
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The final limitation was the cyclical nature of the skin peeling. In the current study, we 
collected skin biopsies from palmar skin that did not appear to be undergoing a peeling cycle 
in an effort to standardise the disease state across the different samples. In part, because of 
this, we were unable to confidently compare the gene expression findings from this study 
with the finding previously done in South Africa samples.  Because KWE has several stages 
throughout the peeing cycles, we would need to collect samples from these different stages 
and evaluate the gene expression and protein abundance during the different stages of the 
peeling cycle to fully understand the disease at the genetic and protein level. 
 
 
4.7.  Future studies 
Further functional studies will be necessary to determine how the overabundance of CTSB in 
the granular layer of the skin leads to the KWE phenotype and why there is variable 
expressivity of the disease phenotype in different individuals, even within the same family.  
Using cultured palmoplantar skin keratinocytes from affected individuals and controls would 
make it possible to examine a range of potential triggers for the erythema and peeling of the 
skin. Such studies could include exposure to stressors and gene expression studies in a 
cellular model of affected and unaffected cell cultures subjected to these stressors.  
 
 
Further, chromatin conformation experiments may be used to determine the validity of our 
hypothesis that both enhancers interact with CTSB under certain conditions or in the 
presence of environmental stimuli.  The conformation experiments would also answer the 
question of whether the chromatin conformation of the region around the enhancer is 
altered and creates different topological domains when the enhancer is duplicated. 
 
 
It would be interesting to do RNA-seq to see which genes and pathways are affected by the 
presence of the enhancer duplication and the overabundance of CTSB in the granular layer. 
Using a genome wide analysis would allow us to determine pathways that are involved in 
keratinisation and the genes that are affected by CTSB. Now that we know which gene and 
protein cause KWE, we may be closer to getting an effective treatment for KWE, however 
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much work would be needed prior to developing an intervention where KWE can be 
effectively treated. It is unlikely that general CTSB inhibition on its own would be effective 
since CTSB appears to be an important protein in keratinisation. In this study we showed 
that CTSB is abundant in the stratum spinosum of normal skin and therefore inhibiting CTSB 
would also lead to inhibition of CTSB in this layer, likely altering the process of keratinisation. 
It is therefore important to determine the pathways that are affected by the overexpression 
of CTSB and the overabundance and ectopic localisation in the granular layer. RNA-seq 
would likely give us a clue of the other genes involved in keratinisation. 
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Chapter 5 
Conclusion 
Twenty years after the localization of the elusive KWE mutation to the KWE critical region 
(8p23.1-22), we have finally identified the causal mutation for KWE. Using next generation 
sequencing (targeted resequencing), we amplified and sequenced the entire KWE critical 
region (8p23.1-22) and identified a 7.67 kb tandem duplication that segregated completely 
with the disease in South African families. Furthermore, this tandem duplication overlaps 
with and independently identified tandem duplication in two Norwegian families. The two 
duplications overlap at an enhancer element that that is active in keratinocytes suggesting 
that the duplication of the enhancer element leads to the KWE phenotype. 
 
 
Using available public data from keratinocyte and breast cancer cell lines, we showed that 
the enhancer is active in a keratinocyte cell line (NHEK) and in differentiating primary 
keratinocytes. The duplicated enhancer occurs in the same topological domain with CTSB 
and two other genes and there was some evidence of the presence of a smaller domain that 
only includes the enhancer and CTSB suggesting that under certain conditions, the enhancer 
may interact exclusively with CTSB and not the other two genes in the domain. Significant 
shifts in the topology of the region, possibly triggered by environmental factors, may drive 
the cells with the duplicated enhancer to favour increased expression of CTSB or any of the 
other genes in the domain. We also showed that the enhancer interacts with CTSB in two 
cancer cell lines but not with the other two genes in the same topological domain and that 
the expression of CTSB correlates with the activity of the enhancer in keratinocytes and 
other cell lines. All these experiments provide evidence suggesting that CTSB is the target 
gene for the enhancer in the absence of the duplication. We showed that CTSB is 
overexpressed in affected skin but not in the skin of healthy individuals. This overexpression 
of CTSB leads to the ectopic localisation and overabundance of the CTSB protein in the 
granular layer of the epidermis leading to KWE. Although the role of CTSB in the epidermis is 
not well understood, we are now one step closer to fully understanding KWE pathogenesis 
and finding an effective treatment.  
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Appendix B: Gentra Puregene DNA purification protocol for buccal swabs 
 
Sample Collection and Handling 
 
1. Pipette 300l Cell Lysis Solution (Puregene Kit) into a 1.5 ml centrifuge tube.  
2. Scrape inside of mouth with provided sterile nylon bristle cytology brush (~ 10 
strokes). 
3. Place brush into 1.5 ml centrifuge tube containing 300 μl Cell Lysis Solution and swirl 
gently to facilitate removal of lysate from the collection brush head into the solution.  
Remove brush from Cell Lysis Solution, scraping the brush on the sides of the tube. 
4. Proceed with DNA purification or store sample (Samples are stable in Cell Lysis 
Solution for at least 2 years at room temperature). 
 
DNA Purification from buccal brush using Puregene DNA purification kit 
(Expected yield: 0.2g DNA) 
 
Step 1: Cell Lysis 
 
1. Incubate sample @ 65C for 15-60 minutes.  For maximum yield add 3l Proteinase K 
Solution (10mg/ml) to the cell lysate, mix by inverting 25 times, incubate @ 55C for 
1 hour or overnight.   
 
Step 2: RNase treatment 
 
1. Add 1.5l RNase A Solution (Puregene kit) to the cell lysate in the microfuge tube. 
2. Invert the tube ~25 times and incubate @ 37C for 15-60 minutes. 
 
Step 3: Protein Precipitation 
 
1. Cool sample to room temperature by placing on ice for 1 minute. 
2. Add 100l Protein Precipitation Solution (Puregene kit) to the sample. 
3. Vortex vigorously at high speed (20 sec) to ensure uniform mixing of the Protein 
Precipitation Solution and the sample. 
4. Place tube on ice for 5 minutes. 
5. Centrifuge @ 13 000 – 16 000 x g for 3 minutes.  The protein should precipitate and 
form a tight white pellet.  If pellet is not tight, repeat steps 3 – 5. 
 
Step 4: DNA Precipitation 
 
1. Pour the supernatant (containing the DNA) into a clean 1.5 ml microfuge tube 
containing 300l 100% Isopropanol (2-propanol) and 0.5l Glycogen Solution 
(20mg/ml, Genta catalog number R-5010).  (The pellet that is left behind in the first 
tube contains the proteins and can be discarded). 
2. Mix by inverting gently 50 times and incubate at room temperature for at least 5 
minutes. 
3. Centrifuge at 12 000 x g for 5 minutes.  (In the case of high yield, the DNA may be 
visible as a small white pellet). 
 
 
92 
 
4. Pour off supernatant and drain tube on clean paper towel.  Add 300l 70% Ethanol 
and invert tube several times to wash DNA. 
5. Centrifuge at 13000 – 16 000 x g for 1 minute.  Carefully pour off supernatant.  (The 
pellet might be loose, therefore care must be taken not to pour the pellet out of the 
tube) 
6. Invert tube and drain on paper towel. Allow to air dry 10 – 15 minutes 
 
Step 5: DNA hydration 
 
1. Add 20 l DNA Hydration Solution (Puregene kit) (20l will give a concentration of 
50ng/l if the yield is 1g DNA) 
2. Rehydrate DNA by incubating sample for 1 hour at 65C or overnight at room 
temperature.  Tube must be tapped periodically to aid dispersing of DNA 
3. Store DNA at 4C (For long term storage sample must be placed at -20C / -70C). 
 
 
DNA Concentration and Quality Assessment  
1. The DNA concentration is determined by spectrophotometry using the Nanodrop ND-
1000. 
Sample Storage 
1. The sample is stored at 4C until required. 
 
 
References: 
Puregene DNA purification kit manual 
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Appendix C: Per base sequence quality 
 
 
 
Figure C2: Per base sequence quality: Targeted Capture Sequencing 
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Appendix D: Pindel programming 
 
Using sequence reads from the targeted linkage region, BWA was used to align the reads using 
"mem" method. The BAM files resulting from the alignment were passed through the version of 
Pindel downloaded from the Pindel github site (https://github.com/genome/pindel) on August 
26, 2014 (commit da6a1ec336fa7159bce0813eb48c19ba76d40116). The options (-T 2  -s  -x 6  --
report_long_insertions  --report_breakpoints  --IndelCorrection) were used.  The output results 
were parsed into individual components for each structural variant. These components were 
loaded into a relational database that included de-identified information about each patient. 
Simple SQL queries were issued against the database that counted the number of times each 
variant occurred grouped by disease status.   
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Appendix E: Protocol for validating the tandem duplication 
 
E1. Primer design 
A. Tandem duplication junction sequence 
PCR primers were for the tandem duplication junction sequence (TDJS) and the control primer 
sets were designed using Primer 3 (version 0.4.0) software (Untergasser et al., 2012). The 
primer sets and PCR product size for the junction sequence amplicon are shown in Table E1. The 
Primer 3 input sequence was created by merging ~1200 bp of sequence from the start of the 
duplicated regions and ~1200 bp before the end of the duplicated region to create a 2328 bp 
sequence with the junction of the two ends of the duplicated region, indicated by square 
bracket. The sequence starts with bases from the end of the duplication and this is merged with 
the start of the duplication thereby creating the junction sequence seen in individuals with the 
duplication (the sequence is shown below). DNA sequences were retrieved in FASTA format 
from NCBI using the coordinates (GRCh37/hg19) of the duplicated region. UCSC In-Silico PCR 
was used to determine if the primer pairs would yield a PCR product using the default settings. 
Because these primers are far away from each other on the normal chromosome, no PCR 
product was predicted by the program as expected (Kent et al., 2002). The junction sequence of 
the duplicated region is unique and would only be present in individuals with the duplication.  
 
 
Table  E1: PCR primer sets and PCR product sizes for the junction sequence amplicon 
Amplicon Direction Primer sequence PCR product 
size (kb) 
Junction 
sequence 
amplicon 
Forward 5’ CTAGGCTTGCAGTGTTGGTC 3’ 
375 
Reverse 5’ GTTAAATCAGGCTGGGCGAG 3’ 
Control 
Forward 5’ AGCCAAGGCAAAATTGAGG 3’ 
250 
Reverse 5’ TCCAGCCGATCTCTCTGTTC 3’ 
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Input sequence for Primer3 
 
GAATCATAGTGAGTTTAGACTTTTCTGGAGGCTTAGGGGTAGGCAATGAGGATGAGGAGG 
GGGTGACCAAGAGATAGAGGAGAGATTTACTTGGTAGAAATGCATCCAGAACACAGGCAT 
TGCCTTTCAGTTAACGTTCTTTGGTGACCCTTCCAGGCTAGATTTCATTTCACTCTGAAC 
TTCCCATCTTTTTGGTTCCCTTTCGCCCTCATTCTCAGATTTCTCTCCATTCCTTTCAGT 
GGCAAAACAACTCATTTCTTCCCTGTTCCCCCAAGAACAGCCTCCCTCATGATCTGCAGG 
CTCAGAGCTGACTTTCGTCCCACAAGATGTCATCTTCCCCAACCAAGTCTCTCTACGCTA 
AAGATAGTTCCTTCACTGGTTAGAGTTCTGGGGCCAGCTGTTCTCTCTCTTTTTAATTTC 
ACTTCTCTAGAAAAGCTTCTTAAGAAATTGCAACCTTGCTTAGCTCAACGGAGGGGGTCA 
GGGCAGTACTGCTGGTGGGGTCATGTGGGCCTGAACACCCCATCTTCTTGTGGCTTCCAT 
GGTTCCCGATATGCCTATAGGAAGCAGACGGGCTGGCCAAAGGGGCGCCCAGCAGGGAGA 
TAATGGGCGTGGGGTGGGCCCCTTTTTCTCTGTTGGCCTGGTCTGGTGCTGGTGTCCCAT 
AAGCTCTCCCAGACGAATAACCTTGTTCTACAAACGTACCCACTTAGGCAATTTGCCCTA 
AAGTTTCATCTTAAAAATGCATGTGAAATTGGACTTGTACTCCAGAGATATCCATGTTTG 
TATTCATGTAAAAATAATGTCCTTCTTAATTATCTGGGGGTGGTGGTGTGTGCCTTTAGT 
GCCAGCTACTTGGAAGGCTGAGGCAGGAGAATCACTTGGACCAAGGAGGCAGAGGTTGCA 
GTGAGCTGAGATCGCGCCATTGCACTCCAGCCTGGGTGACAGAGAGAGACTCTGTCCCAA 
AAAATAAAATAAAATAAAAATAAATACATAAAATAAAATAAAATAAAAGTCCTTCTCTAG 
GCTTGCAGTGTTGGTCTATTATTTTGCCTCCTGTGTGCCAGGCACTGCAGCAGGCAGTGG 
GAACTGAATGTCAGCCCACCTGGAATGGAACTTGGGTCTAGGTTGGAG[AA]GACAGGGT 
TTCACCATGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCGTGATCCACC 
TGCCTCGGCCCCCCAAAGTGCTGGGATTACAGGCGTGAGCCACAGGGCCCAGCCTAATTT 
TGTATTTTTTGTAGAGACGGTGTTTTCCCATGTTGCCCAGGCTGATCTCAAGCTCTTGAG 
CTCAAATGATCCTGCTGTCTCCGCCTCTCAAAGTGCTAGGATTACAGGTGTGAGCCACCT 
CGCCCAGCCTGATTTAACTTTTTAATTTTTAAAAATTATCCTTGAATACGCTACAGTGCC 
CAACTATTCAGTGTTGAAATGAACTGGATTTCTTATTTGGCTGTGATTGTTTCCAGTATT 
TTCAGAAATATGTCTCCATTCCTATCTAAACTCTAAGTTGGTTGGTGTAGGGTGCTGTCT 
TATTCATTTATATTTCTCCTTCCTCTCTTCTCAAAGGACTTTCGTGCCCTTTACCCCTCC 
TTCCAGCAGGGAGGTATGAGCCGTGCCTCTGGGCTCCTTCTTCTTCCTCCCGACAGCTCC 
CTTTCTGTGGTGTGACTGTCATCAGAGGGAGGGAAATTACAGTGCCTTGGCTTCAGAGAA 
CTAAGTTTCTGGTTCTAGCCTTATGAGGGCTGACCACATTGTTTTTTTTTTTTTTCTATT 
GGCTTCCAGAAGGATTCCTCTTTATTCTCCTACAGTGTCTCCTTTGTGGCTTATCCTACT 
GCGAGAGCACTTGTTTAACTGCGAGCAAAAGAGATGGCTGCTCCTCTAATACCGGTGGGG 
GCCTCGACTTTCACATGAACTCCCTCGGAAGGGAAGCCATGTCTGCAGCCAGGGTCTCAG 
CAGATGTCCACAGCCCCCAAAGCTTTGCCTCCAGAGGCCACCACTTCCCACCATTTCTGT 
TTCTGGTGGGGCCCCTTCAATTCTAACTATGGCCTCCCCACCACAGAAGAGCAGGGTTTA 
CTCACTTGTCCTCTTCCATGAAGAGCAAATGTATTATCTCACTTGGGGTTTCAGTTGCCC 
TTGTAGTTTTATTTATTTTTATTTTTCATTTATTTAATTAAAAAAAAAGTTTGAGACAGG 
GTCTCGCTCTGTCACCCAGGCTGGAGTGCAGTGGCAGGATCTTGGCTCACGGCAACCTTC 
ACCTCCCGGGCTCAAGCAATCCTCCCACCTCAGCCTCTGGACTACCTGGGATCACAGACG 
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B.  Primer design: Control primer set 
A control PCR primer set (primers from the LEP gene) was included in the PCR reaction to 
determine PCR efficiency. The control primer set serves to show that the lack of the 
amplification of the TDJS fragment is because the junction is absent and not because the PCR 
failed, since control amplicon is expected in all individuals. PCR product sequence and size were 
determined using UCSC In-Silico PCR (Kent et al., 2002) (Figure E1).  
 
A.  
GAATTAGCTGCAAGGGGAACTAGGAAAAGCTTCTTTAAGGATGGAGAGGCCCTAGTGGAATGGGGAGA
TTCTTCCGGGAGAAGYGATGGATGCRCAGTTGGGCATCCCCACAGACRGACTGGAAAGAAAAAAGGCCT
GGARGAATCAATGTGCAAYGYATGTGTGTTCCCTGGTTCAAGGGCTGGGAACTTTCTCTAMAGGGCCAG
GTAGAAAACATTTTAGGCTTTCTAAGCCAAGGCAAAATTGAGGATATTACRTGGGTASTTATACAACAAR
AATAAACAATTTACACAATTTTTTGTTGACAGAATTCAAAACTTTATAGACACAGAAATGCAAATTTCCTG
TAATTTTYCCRTGAGAACTATTCTTCTTTTGTTTTGTTTTGCGACAGGGTTGY[R]CTGATCCTCYYGCCTCA
GTCTCCCTAAGTGCTGAGATGTTGCAGGAAGTCAGGGACCCCGAACAGAGAGATMRGCTGGAGCCRTG
GCAGAGGAACATAAATTTTGAAGATKTCATTTTAATATGGACACTTWTCAGTTCCCAAATAATAYTTTTAT
AATTTTTTATGCCTGTCTTTGCTTTAATCTCTTAATCCTGTTATCTYCATAAGCTAAGGATGTACRTCACCTC
AGGACCACTGTGATAATTGTGTTAACTGTACAGATTGAYTGCAAAACATGTGTGTTTGAACAATATGAAA
TCAGTGCACCTTGAAAAAGAGCAGAATAACAGCAATTTTTAGGGAACAAGGGAAGACAACTATAAGGTC
TGACTGCCTGCRGGGTCGGGCAAAGGGAGCCA 
 
B. 
Forward and reverse primers highlighted in yellow and blue respectively 
>chr7:127878613+127878862 250bp AGCCAAGGCAAAATTGAGG TCCAGCCGATCTCTCTGTTC 
AGCCAAGGCAAAATTGAGGatattacatgggtacttatacaacaagaata 
aacaatttacacaattttttgttgacagaattcaaaactttatagacaca 
gaaatgcaaatttcctgtaattttcccatgagaactattcttcttttgtt 
ttgttttgcgacagggttgcgctgatcctcccgcctcagtctccctaagt 
gctgagatgttgcaggaagtcagggaccccGAACAGAGAGATCGGCTGGA 
 
Primer melting temperatures 
Forward: 60.2 C agccaaggcaaaattgagg 
Reverse: 60.5 C tccagccgatctctctgttc 
 
Figure E1: rs7799039 control flanking sequence (A) and UCSC in-silico PCR output (B). 
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E2. Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify DNA fragments that encompass the 
tandem duplication junction sequence and the control fragment. PCR reaction mixtures are 
shown in Table E2 and PCR conditions are shown in Table E3. 
 
Table E2: Concentrations and volumes of reagents for PCR reactions 
 Reagent Concentration Volume/ sample 
KAPA Taq ReadyMix 2X 25 
TD_R Primer 10 µM 2 
TD_L Primer 10 µM 2 
Con_R Primer 10 µM 2 
Con_L Primer 10 µM 2 
ddH2O - 15 
DNA 100ng/µl 2 
Total - 50 
 
Table E3: PCR run conditions 
Step Temperature (°C) Time 
Initialisation 95 3 min 
Denaturation 95 30 sec 
Annealing 54 30 sec 
Extension 72 30 sec 
Final extension 72 5 min 
Hold 4 ∞ 
 
Gel electrophoresis on a 3% agarose gel was used to determine if the PCR reaction was 
successful, check if the correct DNA fragment (according to size) was amplified and to check for 
contamination. PCR products were loaded to the solidified 3% agarose gels along with 
Fermentas GeneRuler™ 50 bp DNA ladder by mixing 3 µl Ficoll loading dye with 2 µl of the PCR 
product. The gels were run at 5V/cm for 45 min on Sigma-Aldrich gel tanks and analysed using 
Syngene’s G-Box and GeneSnap (version 6.08) gel documentation system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
                   
34 cycles 
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E3: Post PCR Sequencing protocol 
 
E3.1. Post PCR clean-up 
 Add water to each tube so that the final volume is 100 µl. 
 Transfer all the tubes contents to a clean PCR Clean-up Filter Plates than vacuum until dry 
(approximately 10 minutes). 
 Blot the bottom of the plate with a paper towel.  
 Add 100 µl of ddH2O to each well then vacuum until dry. 
 Blot the bottom of the plate with a paper towel.  
 Add 25 µl of ddH2O to each well then place the tubes on a plate shaker for 10 minutes at 
low speed 
 Move the contents of the well, now containing clean PCR product into clean tubes then 
proceed to cycle sequencing. 
 
 
 
E3.2. Cycle sequencing 
 Set up the cycle sequence reaction. 
 One tube for forward and one tube for reverse for each PCR product. 
 Remember product is light sensitive 
 Cycle sequencing PCR mix (1/8th reaction) 
 
2 µl Cleaned PCR product 
1 µl Bigdye v3.1 (in -20°C freezer with Taq) 
1.5 µl 5x Bigdye buffer  
1 µl Primer (forward OR reverse) 
4.5 µl ddH2O 
10 µl  
 
NB: If sequencing reaction fails either dilute PCR product 1/10 or add 1u PCR 
product and 2 l Big Dye. 
 Cycle sequencing PCR program: 
30 sec   @ 96ºC 
15 sec          @        50ºC             25 cycles 
4 min   @ 60ºC 
                     Hold    @  24ºC 
 
 
E3.1. Post PCR clean-up 
 Add 40 µl injection solution to each tube so that the final volume is 50 µl. 
 Transfer all the tubes contents to a clean PCR Clean-up Filter Plates than vacuum until dry 
(approximately 10 minutes). 
 Blot the bottom of the plate with a paper towel.  
 Add 25 µl of injection solution to each well then vacuum until dry. 
 Blot the bottom of the plate with a paper towel.  
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 Add 10 µl of ddH2O to each well then place the tubes on a plate shaker for five-seven 
minutes at low speed. The cycle sequencing is ligh sensive 
 Move the contents of the well, now containing clean PCR product into clean tubes then 
proceed to cycle sequencing. 
 
 
E4. Sequencing run 
 After denaturing and chilling plate, samples were sequenced on the Applied Biosystems 
3130xl Genetic Analyzer sequencer using default setting and selecting  Z_Seq POP7-36 Ultra 
(for shorter sequences 400-500 bp)  for instrument protocols. 
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Appendix F: In vivo studies 
 
 
F1: RNA Extraction Protocol 
1. Tissue homogenisation 
1.1. The TissueLyser II was used to homogenise the epidermal tissue.  
1.2. Remove RNAlater stabilized tissues from the reagent using forceps. Determine the 
amount of tissue. Do not use more than 30 mg. 
1.3. Place the tissues in 2 ml microcentrifuge tube containing one stainless steel bead (3–7 
mm mean diameter). 
1.4.  Place the tubes at room temperature (15–25°C) then add 600 μl Buffer RLT to each tube 
(add ME to the Buffer RLT before use). 
1.5. Place the tubes in the TissueLyser Adapter Set 2 x 24.  
1.6. Operate the TissueLyser for 2 min at 30 Hz, this was done three time. Disassemble the 
adapter set, rotate the rack of tubes so that the tubes nearest to the TissueLyser are now 
outermost, and reassemble the adapter set. Operate the TissueLyser for another 2 min at 
20–30 Hz. 
 
 
2. RNA extraction 
2.1. Total RNA was extracted using the RNeasy® Mini kit 
2.2. Centrifuge the lysate for 3 min at full speed. Carefully remove the supernatant by 
pipetting, and transfer it to a new microcentrifuge tube (not supplied). Use only this 
supernatant (lysate) in subsequent steps. In some preparations, very small amounts of 
insoluble material will be present after the 3 min centrifugation, making the pellet invisible. 
2.3. Add 1 volume of 70% ethanol to the cleared lysate, and mix immediately by pipetting. 
Do not centrifuge. The volume of lysate may be less than 350 μl or 600 μl due to loss during 
homogenization and centrifugation in the previous steps. Precipitates may be visible after 
addition of ethanol. This does not affect the procedure. 
2.4. Transfer up to 700 μl of the sample, including any precipitate that may have formed, to 
an RNeasy spin column placed in a 2 ml collection tube (supplied). Close the lid gently, and 
centrifuge for 15 s at ≥8000 x g (≥10,000 rpm).  
2.5. 2.4. Discard the flow-through. Reuse the collection tube in step 6.If the sample volume 
exceeds 700 μl, centrifuge successive aliquots in the same RNeasy spin column. Discard the 
flow-through after each centrifugation. 
2.6.  Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge 
for 15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. 
2.7.  Discard the flow-through. Reuse the collection tube in step 2.8. After centrifugation, 
carefully remove the RNeasy spin column from the collection tube so that the column does 
not contact the flow-through. Be sure to empty the collection tube completely. 
2.8.  Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 
15 s at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Discard the flow-
through and reuse the collection tube in step 2.8. (Buffer RPE is supplied as a concentrate. 
Ensure that ethanol is added to Buffer RPE before use). 
2.9. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and centrifuge for 
2min at ≥8000 x g (≥10,000 rpm) to wash the spin column membrane. Note: After 
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centrifugation, carefully remove the RNeasy spin column from the collection tube so that 
the column does not contact the flow-through. Otherwise, carryover of ethanol will occur. 
2.10.  Place the RNeasy spin column in a new 2 ml collection tube (supplied), and discard the 
old collection tube with the flow-through. Close the lid gently, and centrifuge at full speed 
for 1 min. Perform this step to eliminate any possible carryover of Buffer RPE, or if residual 
flow-through remains on the outside of the RNeasy spin column after step 2.11. 
2.11. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 30–50 μl 
RNase-free water directly to the spin column membrane. Close the lid gently, and centrifuge 
for 1 min at ≥8000 x g (≥10,000 rpm) to elute the RNA. 
2.12. Perform quality (Table F1) and quantity (Figure F1) check then store the RNA at -80°C. 
 
 
3. Check RNA Quality and quantity 
3.1. The RNA quantity was determined using the NanoDrop ND-1000 
 
                        Table F1: RNA quantity and quality for all extracted samples 
Sample ID ng/ul 260/280 260/230 
Total RNA 
(ug) 
NOR _Ctr1 51 2,09 1,54 1,3 
NOR _Ctr2 97 2,11 1,04 2,9 
NOR _Ctr3 128 2,09 1,58 3,8 
NOR _Ctr4 121 2,10 0,8 3,6 
OSL_DII-1 208 2,10 1,89 6,3 
OSL_DII-6 129 2,09 1,89 3,9 
OSL_DIII-6 136 2,12 0,85 4,1 
OSL_EI-2 92 2,08 1,32 2,8 
SA_KWE1 13,5 2,07 0,12 0,40 
SA_KWE2 143,1 2,11 1,32 4,29 
SA_KWE3 80,4 2,08 0,62 2,41 
SA_Ctr1 29,8 2,04 0,61 0,89 
SA _Ctr2 39,9 2,12 0,73 1,20 
SA _Ctr3 18,9 1,95 0,39 0,57 
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3.2. The RNA quanlity was determined using the Experion™ 
Total RNA was determined using the automated electrophoresis Experion™ station. 
 
A. South African samples 
 
B. Norwegian samples 
 
Figure F1: Quality check of the extracted RNA showing the ribosomal 18S and 28S subunits along with the ladder. Sample SA_KWE1 
showed the lowest quality. There was evidence of a degree of degradation of the South African samples (lower peaks, particularly for the 
28S peak), but the samples were still usable. The x axis is time (seconds) and the y axis is the fluorescence. 
 
 
 
 
SA_KWE1 
SA_Ctr3 SA_Ctr2 SA_Ctr1 
SA_KWE3 SA_KWE2 
Ladder 
NOR _Ctr1 NOR _Ctr2 NOR _Ctr3 
NOR _Ctr4 OSL_DII-1 OSL_DII-2 OSL_DII-3 
18S 
28S 
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F2. First strand cDNA synthesis 
1.1.  For a single reaction, combine the following components in a tube on ice. Include a 
negative control. 
 
Table F2: Component and volumes for first strand cDNA synthesis 
Component Quantity 
5X VILO™ Reaction Mix 5 μL 
10X SuperScript™ Enzyme Mix 2.5 μL 
RNA  250 ng 
DEPC-treated water* x μL 
Total 25 μL 
*Calculated per sample based on the volume of input RNA (see Table F3) 
 
Table F3.Template dilution for first strand cDNA synthesis 
Sample ID ng/ul Template 250 ng ddH2O 
NOR _Ctr1 51 4.9 12.6 
NOR _Ctr2 97 2.6 14.9 
NOR _Ctr3 128 2.0 15.5 
NOR _Ctr4 121 2.1 15.4 
OSL_DII-1 208 1.2 16.3 
OSL_DII-6 129 1.9 15.6 
OSL_DIII-6 136 1.8 15.7 
OSL_EI-2 92 2.7 14.8 
SA_KWE1 13 17.5 0.0 
SA_KWE2 143 1.7 15.8 
SA_KWE3 80 3.1 14.4 
SA_Ctr1 30 8.3 9.2 
SA _Ctr2 40 6.3 11.3 
SA _Ctr3 19 13.2 4.3 
 
1.2. Gently mix tube contents and incubate at 25°C for 10 minutes.  
1.3.  Incubate tube at 42°C for 60 minutes.  
1.4.  Terminate the reaction at 85°C at 5 minutes. 5. Store at –20°C until use. 
 
 
*Sample NOR _Ctr3 was used for the standard curve and three separate tubes were ran for the 
first strand cDNA generation. All three samples were later mixed together in one tube. 25 µl of 
the cDNA was added to 25 µl ddH2O and was used for serial dilutions for the three test genes 
and the endogenous control. The serial dilution was as follows: Serial dilution: 500, 250, 0125, 
62.5, 13.5.
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F3: Relative gene expression assays 
Work on ice. 
 
Table F4: Reaction mix for gene expression essay for triplicate reactions per sample  
PCR reaction mix component Quantity per triplicate 
20xTaqMan® Gene Expression Assay (Probe) 1.5 μL 
2x TaqMan® Gene Expression Master Mix 15 μL 
cDNA template 3.3 μL 
RNase-free water 13.5 μL 
Total 3.3 μL 
 
Make enough reaction to include triplicate cDNA negative control and qPCR negative control 
 Add 10 µl x3 per sample in a 384 well plate. 
 Sample NOR _Ctr3 was used for the standard curve and three separate tubes were ran 
for the first strand cDNA generation. All three samples were later mixed together in one 
tube. 25 µl of the cDNA was added to 25 µl ddH2O and was used for serial dilutions for 
the three test genes and the endogenous control. The seral dilution was run in triplicate 
for each gene. 
 qPCR was run on the Applied Biosystems 7900HT Fast Real-Time PCR System. 
 Data was initially processed and viewed using SDS software. 
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Appendix G: Reagents and solutions 
 
Primer Dilutions  
ddH2O 90 µl 
100 µM/primer 10 µl 
 100 µl of 10 µM of 
primer 
 
10X TBE buffer 
Tris 108 g 
Boric Acid 55 g 
EDTA 7.44 g 
  Filled solution up to 1L, brought buffer to pH 8.0 and autoclaved it.  
 
3% Agarose Gel 
10X TBE buffer 40 ml 
ddH2O 360 ml 
Agarose 12 g 
  Added 12µl (3 µl/ 100 ml of gel) EtBr when agarose had melted. 
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Appendix H 
 
Link to the paper below:  
 
http://www.cell.com/ajhg/abstract/S0002-9297(17)30144-1  
 
Thandiswa Ngcungcu, Martin Oti, Jan C. Sitek, Bjørn I. Haukanes, Bolan Linghu,  Robert 
Bruccoleri,, Tomasz Stokowy, Edward J. Oakeley, Fan Yang, Jiang Zhu, Marc Sultan, Joost 
Schalkwijk, Ivonne M.J.J. van Vlijmen-Willems, Charlotte von der Lippe, Han G. Brunner, Kari 
M. Ersland,, Wayne Grayson, Stine Buechmann-Moller, Olav Sundnes, Nanguneri Nirmala, 
Thomas M. Morgan, Hans van Bokhoven, Vidar M. Steen, Peter R. Hull, Joseph Szustakowski, 
Frank Staedtler, Huiqing Zhou, Torunn Fiskerstrand, Michèle Ramsay. (2017) Duplicated 
enhancer region increases expression of CTSB and segregates with Keratolytic Winter 
Erythema in South African and Norwegian families. American Journal of Human Genetics, 
100 (5), 737-750. 
 
